MF Researcher Database

Researchers Database

Advance

IMAI YOUICHI

Affiliation： Department of Hematology and Oncology
Position： Professor
Last Updated :2025/06/24

Profiles

Profiles

  • 氏名

    IMAI YOUICHI

Affiliation

  • Department of Hematology and Oncology, Professor

Profile and Settings

Alternate Names

  • Yoichi Imai

Affiliation

  • Dokkyo Medical University, Department of Hematology and Oncology

Research Interests

  • 分子生物学
  • 多発性骨髄腫
  • 白血病・骨髄異形成症候群
  • 血液内科学

Research Areas

  • Life Science, Hematology and medical oncology

Research Experience

  • Mar. 2022, 9999, Dokkyo Medical University, Department of Hematology and Oncology, Professor
  • Jul. 2016, Feb. 2022, The University of Tokyo, Hospital The Institute of Medical Science Research Hospital, Department of Hematology/Oncology, 准教授
  • Oct. 2010, Jun. 2016, Tokyo Women's Medical University, Faculty of Medicine, Faculty of Medicine, 講師
  • Jan. 2008, Sep. 2010, The University of Tokyo, Graduate School of Medicine, 講師
  • Mar. 2004, Dec. 2007, Harvard University, Immune Disease Institute, 研究員
  • Sep. 2002, Feb. 2004, The University of Tokyo, Heamatology and Oncology, Faculty of Medicine University Hospital, 助手
  • Apr. 2001, Aug. 2002, 日本学術振興会, 特別研究員
  • Apr. 1999, Mar. 2001, The University of Tokyo, Heamatology and Oncology, Faculty of Medicine University Hospital, 医員

Education

  • Apr. 1994, Mar. 1999, 東京大学大学院, 医学系研究科, 内科学専攻
  • Apr. 1988, Mar. 1992, The University of Tokyo, Faculty of Medicine, School of Medicine

Committee Memberships

  • Jun. 2024
  • 2022, 9999
  • 2022, 9999
  • Jan. 2020, 9999, Society
  • 9999, Society
  • 9999, Society
  • Sep. 2020, May 2022
  • 2015, 2020, Society
  • 2018, 2019, Society
  • Society

Association Memberships

  • 米国血液学会
  • THE MOLECULAR BIOLOGY SOCIETY OF JAPAN
  • THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER
  • THE JAPANESE CANCER ASSOCIATION
  • 日本造血細胞移植学会
  • 日本骨髄腫学会
  • THE JAPANESE SOCIETY OF HEMATOLOGY
  • THE JAPANESE SOCIETY OF INTERNAL MEDICINE

Research achievements

Awards

  • Jan. 2014, IMF (International Myeloma Foundation), IMF-JAPAN Special Research Grant, Development of novel targeted therapies in the treatment of multiple myeloma through elucidation of molecular mechanism of oncogenesis mediated by calcineurin, Imai Yoichi
  • Nov. 2001, 日本臨床血液学会, 奨励賞, 骨髄異形成症候群におけるAML1遺伝子異常の解析, 今井 陽一
  • Apr. 2001, 日本血液学会, 奨励賞, Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis, 今井 陽一
  • Apr. 2001, 日本内科学会, 奨励賞, ヒト造血器腫瘍におけるSmad遺伝子の変異解析, 今井 陽一

Published Papers

    Original paper
  • The levels of serum soluble CD86 are correlated with the expression of CD86 variant 3 gene and are prognostic indicators in patients with myeloma., Ryosuke Kinoshita; Mariko Ishibashi; Hiroshi Handa; Makoto Sasaki; Yoichi Imai; Norina Tanaka; Shigeki Ito; Mika Sunakawa-Kii; Yuta Kaito; Toshio Asayama; Norio Komatsu; Junji Tanaka; Takeshi Odajima; Hiroki Sugimori; Hiroki Yamaguchi; Koiti Inokuchi; Hideto Tamura, Experimental hematology, 14 Feb. 2023
    DOI
  • Strategy for maintenance therapy for transplant-eligible and non-eligible patients with multiple myeloma., Imai Y; Handa T; Mitani K, Dokkyo Medical Journal, 2023
  • 多発性骨髄腫における免疫療法の基礎と臨床―新規治療も含めてー, 今井陽一, 臨床血液, 63, 1180-1187, Sep. 2022
  • ST合剤内服中にもかかわらず、Nocardia nova肺炎を併発したATLの1例, 川俣 豊隆; 櫻井 健一; 大貝 明日香; 磯部 優理; 佐藤 亜紀; 横山 和明; 小沼 貴晶; 加藤 せい子; 安井 寛; 今井 陽一; 高橋 聡; 内丸 薫; 南谷 泰仁, 臨床血液, 63(5), 510-510, May 2022
  • ST合剤内服中にもかかわらず、Nocardia nova肺炎を併発したATLの1例, 川俣 豊隆; 櫻井 健一; 大貝 明日香; 磯部 優理; 佐藤 亜紀; 横山 和明; 小沼 貴晶; 加藤 せい子; 安井 寛; 今井 陽一; 高橋 聡; 内丸 薫; 南谷 泰仁, 臨床血液, 63(5), 510-510, May 2022
  • RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia., Tatsuya Masuda; Shintaro Maeda; Sae Shimada; Naoya Sakuramoto; Ken Morita; Asami Koyama; Kensho Suzuki; Yoshihide Mitsuda; Hidemasa Matsuo; Hirohito Kubota; Itaru Kato; Kuniaki Tanaka; Junko Takita; Masahiro Hirata; Tatsuki R Kataoka; Tatsutoshi Nakahata; Souichi Adachi; Hideyo Hirai; Shuichi Mizuta; Kazuhito Naka; Yoichi Imai; Shinya Kimura; Hiroshi Sugiyama; Yasuhiko Kamikubo, Cancer science, 113(2), 529-539, Feb. 2022
    DOI
  • Thiamine Deficiency and Neurological Symptoms in Patients with Hematological Cancer Receiving Chemotherapy: A Retrospective Analysis, Yohei Iimura; Shohei Andoh; Toyotaka Kawamata; Aki Sato; Kazuaki Yokoyama; Yoichi Imai; Arinobu Tojo; Masanori Nojima; Munetoshi Sugiura; Seiichiro Kuroda, Journal of Neurosciences in Rural Practice, 12(04), 726-732, Oct. 2021
    DOI
  • KIT D816V変異陰性侵襲性全身性肥満細胞症の一例(A case of KIT D816V mutation negative aggressive systemic mastocytosis), 梨本 淳一郎; 佐藤 亜紀; 櫻井 健一; 岡部 基人; 磯部 優理; 川俣 豊隆; 小沼 貴晶; 横山 和明; 安井 寛; 大田 泰徳; 高橋 聡; 今井 陽一; 東條 有伸, 日本血液学会学術集会, 83回, PS-3, Sep. 2021
  • 急性リンパ性白血病移植後における腫瘍由来循環DNAの有用性(Prognostic impact of circulating tumor DNA status post-allogeneic HSCT in ALL), 小川 弥穂; 横山 和明; 高橋 華; 伊藤 美香; 遊佐 希; 清水 英悟; 片山 琴絵; 岡部 基人; 磯部 優理; 小沼 貴晶; 今井 陽一; 井元 清哉; 高橋 聡, 日本血液学会学術集会, 83回, OS1-5, Sep. 2021
  • A case of KIT D816V mutation negative aggressive systemic mastocytosis(和訳中), 梨本 淳一郎; 佐藤 亜紀; 櫻井 健一; 岡部 基人; 磯部 優理; 川俣 豊隆; 小沼 貴晶; 横山 和明; 安井 寛; 大田 泰徳; 高橋 聡; 今井 陽一; 東條 有伸, 日本血液学会学術集会, 83回, PS-3, Sep. 2021
  • Prognostic impact of circulating tumor DNA status post-allogeneic HSCT in ALL(和訳中), 小川 弥穂; 横山 和明; 高橋 華; 伊藤 美香; 遊佐 希; 清水 英悟; 片山 琴絵; 岡部 基人; 磯部 優理; 小沼 貴晶; 今井 陽一; 井元 清哉; 高橋 聡, 日本血液学会学術集会, 83回, OS1-5, Sep. 2021
  • Association between thiamine decrease and neuropsychiatric symptoms in gastrointestinal and hematological cancer patients receiving chemotherapy., Iimura Y; Kurokawa T; Andoh S; Kanemoto Y; Kawamata T; Yazawa K; Sato A; Yokoyama K; Imai Y; Tsurita G; Ahiko Y; Aikou S; Shida D; Nojima M; Tojo A; Sugiura M; Kuroda S, Biomedicine & Pharmacotherapy, Jul. 2021
  • 古典的ホジキンリンパ腫診断時に合併を認めた多発性骨髄腫, 安藤 匠平; 横山 和明; 内田 三四郎; 牧山 純也; 川俣 豊隆; 安井 寛; 大田 泰徳; 今井 陽一; 東條 有伸, 臨床血液, 62(1), 14-19, Jan. 2021
  • CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia., Kaito Y; Hirano M; Futami M; Nojima M; Tamura H; Tojo A; Imai Y, Oncology Letters, 2021
  • [Cooccurrence of classic Hodgkin lymphoma and multiple myeloma]., Shohei Andoh; Kazuaki Yokoyama; Sanshiro Uchida; Junya Makiyama; Toyotaka Kawamata; Hiroshi Yasui; Yasunori Ota; Yoichi Imai; Arinobu Tojo, [Rinsho ketsueki] The Japanese journal of clinical hematology, 62(1), 14-19, 2021
    DOI
  • Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse., Yasui H; Kobayashi M; Sato K; Kondoh K; Ishida T; Kaito Y; Tamura H; Handa H; Tsukune Y; Sasaki M; Komatsu N; Tanaka N; Tanaka J; Kizaki M; Kawamata T; Makiyama J; Yokoyama K; Imoto S; Tojo A; Imai Y, International Journal of Clinical Oncology, 26(11), 2142-2150, 2021
    DOI
  • Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation., Kaito Y; Konuma T; Monna-Oiwa M; Kato S; Isobe M; Okabe M; Imai Y; Takahashi S; Tojo A, International Journal of Laboratory Hematology, 43(6), 1437-1442, 2021
    DOI
  • Expression of activated integrin b7 in multiple myeloma patients., Hosen N; Yoshihara S; Takamatsu H; Ri M; Nagata Y; Kosugi H; Shimomura Y; Hanamura I; Fuji S; Minauchi K; Kuroda J; Suzuki R; Nishimura N; Uoshima N; Nakamae H; Kawano Y; Mizuno I; Gomyo H; Suzuki K; Ozaki S; Nakamura S; Imai Y; Kizaki M; Negoro E; Handa H; Iida S, International Journal of Hematology, 114(1), 3-7, 2021
    DOI
  • RUNX inhibitor suppresses graft-versus-host disease through targeting RUNX-NFATC2 axis., Kubota H; Masuda T; Noura M; Furuichi K; Matsuo H; Hirata M; Kataoka TR; Hiramatsu H; Yasumi T; Nakahata T; Imai Y; Takita J; Adachi S; Sugiyama H; Kamikubo Y, eJHaem, 2(3), 449-458, 2021
    DOI
  • Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma., Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A, Journal of Experimental & Clinical Cancer Research, 40(1), 110-110, 2021
    DOI
  • L-Arginine prevents cereblon-mediated ubiquitination of glucokinase and stimulates glucose-6-phosphate production in pancreatic -cells., Cho J; Horikawa Y; Enya M; Takeda J; Imai Y; Imai Y; Handa H; Imai T, Communications Biology, 3, 497, Sep. 2020
  • Latest Development in Multiple Myeloma., Imai Y, Cancers, Sep. 2020
  • 診断時に細胞表面形質の異なる2つの細胞集団を認めた治療抵抗性多発性骨髄腫, 安藤 匠平; 川俣 豊隆; 佐藤 亜紀; 横山 和明; 安井 寛; 今井 陽一; 東條 有伸, 臨床血液, 61(8), 990-990, Aug. 2020
  • Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience., Masayuki Kobayashi; Shohei Ando; Toyotaka Kawamata; Junya Makiyama; Kazuaki Yokoyama; Yoichi Imai; Arinobu Tojo, International journal of hematology, 112(2), 185-192, Aug. 2020
    DOI
  • 診断時に細胞表面形質の異なる2つの細胞集団を認めた治療抵抗性多発性骨髄腫, 安藤 匠平; 川俣 豊隆; 佐藤 亜紀; 横山 和明; 安井 寛; 今井 陽一; 東條 有伸, 臨床血液, 61(8), 990-990, Aug. 2020
  • UGGT1 retains proinsulin in the endoplasmic reticulum in an arginine dependent manner., Cho J, Hiramoto M, Masaike Y, Sakamoto S, Imai Y, Imai Y, Handa H, Imai T., Biochemical and Biophysical Research Communications, May 2020
  • The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells, Muneyoshi Futami; Keisuke Suzuki; Satomi Kato; Saori Ohmae; Yoshio Tahara; Masanori Nojima; Yoichi Imai; Takayuki Mimura; Yoshihiro Watanabe; Arinobu Tojo, PLOS ONE, 15(4), e0231896-e0231896, 22 Apr. 2020
    DOI
  • Notch1–JAG1 signaling induces aggressive myeloma cell behaviors, Ishibashi M; Ueda K; Imai Y; Inokuchi K; Morita R; Tamura H, International Journal of Myeloma, Feb. 2020
  • Fractionated Ifosfamide, Carboplatin, and Etoposide with Rituximab as a Safe and Effective Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Severe Comorbidities., Tanaka N; Imai Y; Yoshinaga K; Shiseki M; Tanaka J, Annals of Hematology, 99(11), 2577-2586, 2020
    DOI
  • High prevalence of left ventricular non-compaction and its impact on chemotherapy-related cardiac dysfunction in patients with hematological diseases., Hirano M; Kimura K; Ishigaki T; Nojima M; Daimon M; Morita H; Takenaka K; Xu B; Sawada N; Hirokawa M; Komuro I; Morisaki T; Yotsuyanagi H; Kawamata T; Yokoyama K; Konuma T; Kato S; Yasui H; Nagamura-Inoue T; Uchimaru K; Takahashi S; Imai Y; Tojo A, Circulation Journal, 84(11), 1957-1964, 2020
    DOI
  • Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy, Takashi Matsukawa; Tomotaka Yamamoto; Akira Honda; Takashi Toya; Hiroyuki Ishiura; Jun Mitsui; Masaki Tanaka; Akihito Hao; Akihito Shinohara; Mizuki Ogura; Keisuke Kataoka; Sachiko Seo; Keiki Kumano; Masataka Hosoi; Kensuke Narukawa; Megumi Yasunaga; Hiroaki Maki; Motoshi Ichikawa; Yasuhito Nannya; Yoichi Imai; Tsuyoshi Takahashi; Yuji Takahashi; Yuki Nagasako; Kyoko Yasaka; Kagari Koshi Mano; Miho Kawabe Matsukawa; Toji Miyagawa; Masashi Hamada; Kaori Sakuishi; Toshihiro Hayashi; Atsushi Iwata; Yasuo Terao; Jun Shimizu; Jun Goto; Harushi Mori; Akira Kunimatsu; Shigeki Aoki; Shin Hayashi; Fumihiko Nakamura; Syunya Arai; Kazunari Momma; Katsuhisa Ogata; Toshikazu Yoshida; Osamu Abe; Johji Inazawa; Tatsushi Toda; Mineo Kurokawa; Shoji Tsuji, Brain Communications, 2(1), 01 Jan. 2020
    DOI
  • Feasibility study to establish diagnostic biomarkers for relapsed refractory multiple myeloma, Yasui, Hiroshi; Kobayashi, Masayuki; Sato, Kota; Ishida, Tadao; Tamura, Hideto; Handa, Hiroshi; Sasaki, Makoto; Kawamata, Toyotaka; Makiyama, Junya; Yokoyama, Kazuaki; Tojo, Arinobu; Imai, Yoichi, CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 19(10), E84-E84, Oct. 2019
    DOI
  • 多発性骨髄腫における治療抵抗性バイオマーカーの探索(Establishment of diagnostic biomarkers for relapsed refractory multiple myeloma), 小林 真之; 安井 寛; 佐藤 広太; 石田 禎夫; 田村 秀人; 半田 寛; 佐々木 純; 川俣 豊隆; 牧山 純也; 横山 和明; 東條 有伸; 今井 陽一, 日本癌学会総会記事, 78回, P-1356, Sep. 2019
  • 多発性骨髄腫においてNOTCH1とJAG1の相互作用が増悪化を誘導する(The interaction of NOTCH1 with JAG1 induces aggressive myeloma behavior), 上田 圭馬; 石橋 真理子; 今井 陽一; 猪口 孝一; 田村 秀人, International Journal of Myeloma, 9(1), 85-85, May 2019
  • 血清KL-6値は多発性骨髄腫の予後予測因子となりうる(KL-6 may be an excellent predictor of prognosis in multiple myeloma), 砂川 実香; 石橋 真理子; 海渡 裕太; 木下 量介; 朝山 敏夫; 守屋 慶一; 半田 寛; 佐々木 純; 今井 陽一; 田中 紀奈; 伊藤 薫樹; 田野崎 栄; 田中 淳司; 小松 則夫; 猪口 孝一; 田村 秀人, International Journal of Myeloma, 9(1), 86-86, May 2019
  • HDAC inhibitors exert anti-myeloma effects through multiple modes of action., Imai Y; Hirano M; Kobayashi M; Futami M; Tojo A; corresponding author, Cancers, 11(475), doi:10.3390/cancers11040475, Apr. 2019
    DOI
  • Safety of lenalidomide, dexamethasone, and cyclophosphamide in elderly Japanese patients with relapsed and refractory multiple myeloma: results of phase 1 study., Tsukune Y; Sasaki M; Isoda A; Ando J; Koike M; Matsumoto M; Sawamura M; Tamura H; Handa H; Imai Y; Yahata Y; Komatsu N, International Journal of Myeloma, 9, 1-6, 2019
  • Nested polymerase chain reaction with specific primers for Mucorales in the serum of patients with hematological malignancies., Hirano M; Ota Y; Koibuchi T; Takei T; Takeda R; Kawamata T; Yokoyama K; Uchimaru K; Yotsuyanagi H; Imai Y; Tojo A; corresponding author, The Japanese Journal of Infectious Diseases, 2019
  • SLAMF3-mediated signaling via ERK pathway activation promotes aggressive myeloma behaviors in multiple myeloma., Ishibashi M; Takahashi R; Tsubota A; Sasaki M; Handa H; Imai Y; Tanaka N; Tsukune Y; Tanosaki S; Ito S; Asayama T; Sunakawa M; Kaito Y; Kuribayashi-Hamada Y; Kondo-Onodera A; Moriya K; Komatsu N; Tanaka J; Odajima T; Sugimori H; Inokuchi K; Tamura H, Molecular Cancer Research, 2019
  • Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system., Miho Ogawa; Kazuaki Yokoyama; Mitsuhito Hirano; Koji Jimbo; Kiyosumi Ochi; Toyotaka Kawamata; Nobuhiro Ohno; Eigo Shimizu; Nozomi Yokoyama; Rui Yamaguchi; Seiya Imoto; Kaoru Uchimaru; Naoto Takahashi; Satoru Miyano; Yoichi Imai; Arinobu Tojo, British journal of haematology, 183(5), 842-845, Dec. 2018
    DOI
  • Clinical impact of serum soluble SLAMF7 in multiple myeloma., Mariko Ishibashi; Saori Soeda; Makoto Sasaki; Hiroshi Handa; Yoichi Imai; Norina Tanaka; Sakae Tanosaki; Shigeki Ito; Takeshi Odajima; Hiroki Sugimori; Toshio Asayama; Mika Sunakawa; Yuta Kaito; Ryosuke Kinoshita; Yasuko Kuribayashi; Asaka Onodera; Keiichi Moriya; Junji Tanaka; Yutaka Tsukune; Norio Komatsu; Koiti Inokuchi; Hideto Tamura, Oncotarget, 9(78), 34784-34793, 05 Oct. 2018
    DOI
  • 多発性骨髄腫におけるNOTCHシグナルと病態進行の関連(Association between NOTCH signaling and disease progression in multiple myeloma), 上田 圭馬; 石橋 真理子; 田村 秀人; 今井 陽一; 高橋 秀実; 猪口 孝一, 臨床血液, 59(9), 1670-1670, Sep. 2018
  • Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial, Atsushi Isoda; Kayoko Murayama; Shigeki Ito; Yoichi Kohara; Masaki Iino; Yuri Miyazawa; Morio Matsumoto; Hiroshi Handa; Yosuke Imai; Takuro Ishiguro; Wataru Izumita; Kiyoshi Kitano; Yukio Hirabayashi; Hideyuki Nakazawa; Fumihiro Ishida; Toru Mitsumori; Keita Kirito; Takaaki Chou; Hirokazu Murakami; For the Kanshinetsu Multiple Myeloma Study Group, International Journal of Hematology, 108(1), 39-46, 01 Jul. 2018
    DOI
  • Secondary syphilis with tonsillar and cervical lymphadenopathy and a pulmonary lesion mimicking malignant lymphoma, Yukiko Komeno; Yasunori Ota; Tomohiko Koibuchi; Yoichi Imai; Kuniko Iihara; Tomiko Ryu, American Journal of Case Reports, 19, 238-243, 04 Mar. 2018
    DOI
  • Nonmyelomatous ascites resulting from the increased secretion of vascular endothelial growth factor in multiple myeloma, Hiroaki Maki; Yasuhito Nannya; Yoichi Imai; Satoko Yamaguchi; Yasuhiko Kamikubo; Motoshi Ichikawa; Fumihiko Nakamura; Mineo Kurokawa, Internal Medicine, 57(5), 725-727, 2018
    DOI
  • Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation., Hirano M; Jimbo K; Ogawa M; Ochi K; Makiyama J; Kawamata T; Yokoyama K; Tanaka T; Inamoto Y; Yamano Y; Fukuda T; Uchimaru K; Imai Y; Tojo A; corresponding author, Bone Marrow Transplantation, 53(11), 1470-1473, 2018
    DOI
  • Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation., Wang YH; Imai Y; Shiseki M; Tanaka J; Motoji T, Leuk Res, 67, 99-108, 2018
  • 自家末梢血幹細胞移植が奏効したK-RAS/N-RAS変異陽性double-refractory myeloma, 神保 光児; 横山 和明; 小川 弥穂; 平野 光人; 越智 清純; 小林 真之; 遊佐 希; 清水 英悟; 川俣 豊隆; 安井 寛; 大野 伸広; 山口 類; 井元 清哉; 古川 洋一; 宮野 悟; 今井 陽一; 東條 有伸, 臨床血液, 58(12), 2380-2385, Dec. 2017
  • Hypersensitivity reaction to beta-lactam antibiotics in patients with adult T- cell leukemia/lymphoma treated with mogamulizumab, Takeo Yasu; Yoichi Imai; Nobuhiro Ohno; Kaoru Uchimaru; Yosuke Kurokawa; Arinobu Tojo, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 55(10), 807-810, Oct. 2017
    DOI
  • RAS変異陽性double-refractory myelomaに自家末梢血幹細胞移植が奏効した1例, 神保 光児; 横山 和明; 小川 弥穂; 平野 光人; 越智 清純; 小林 真之; 遊佐 希; 清水 英悟; 川俣 豊隆; 安井 寛; 大野 伸広; 山口 類; 井元 清哉; 古川 洋一; 宮野 悟; 今井 陽一; 東條 有伸, 臨床血液, 58(8), 1074-1074, Aug. 2017
  • Different clonal evolution of chronic myeloid leukemia between bone marrow and the central nervous system., Ogawa M; Yokoyama K; Hirano M; Jimbo K; Ochi K; Kawamata T; Ohno N; Shimizu E; Yokoyama N; Yamaguchi R; Imoto S; Uchimaru K; Miyano S; Imai Y; Tojo A; corresponding author, Br J Haematol, 2017
  • Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies, Yoichi Imai; Yoshiro Maru; Junji Tanaka, CANCER SCIENCE, 107(11), 1543-1549, Nov. 2016
    DOI
  • Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine, Noriko Isono; Yoichi Imai; Aya Watanabe; Keiichi Moriya; Hideto Tamura; Koiti Inokuchi; Chihiro Asano; Michihiko Masuda; Hanae Shimura; Kenjiro Mitsuhashi; Hiroshi Kazama; Hiroki Sugimori; Toshiko Motoji; Junji Tanaka, LEUKEMIA & LYMPHOMA, 57(9), 2204-2207, Sep. 2016
    DOI
  • Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents' era, Yutaka Tsukune; Makoto Sasaki; Takeshi Odajima; Atsushi Isoda; Morio Matsumoto; Michiaki Koike; Hideto Tamura; Keiichi Moriya; Shigeki Ito; Maki Asahi; Yoichi Imai; Junji Tanaka; Hiroshi Handa; Hiromi Koiso; Sakae Tanosaki; Jian Hua; Masao Hagihara; Yuriko Yahata; Satoko Suzuki; Sumio Watanabe; Hiroki Sugimori; Norio Komatsu, ANNALS OF HEMATOLOGY, 95(9), 1465-1472, Sep. 2016
    DOI
  • Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma., Yoichi Imai; Eri Ohta; Shu Takeda; Satoko Sunamura; Mariko Ishibashi; Hideto Tamura; Yan-Hua Wang; Atsuko Deguchi; Junji Tanaka; Yoshiro Maru; Toshiko Motoji, JCI insight, 1(5), e85061, 21 Apr. 2016
    DOI
  • Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan, Hiroki Ishihara; Tomokazu Shimizu; Kohei Unagami; Toshihito Hirai; Daisuke Toki; Kazuya Omoto; Masayoshi Okumi; Yoichi Imai; Hideki Ishida; Kazunari Tanabe, THERAPEUTIC APHERESIS AND DIALYSIS, 20(2), 165-173, Apr. 2016
    DOI
  • Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine, Isono N; Imai Y; Watanabe A; Moriya K; Tamura H; Inokuchi K; Asano C; Masuda M; Shimura H; Mitsuhashi K; Kazama H; Sugimori H; Motoji T; Tanaka J, Leuk Lymph, 24, 1-4, Dec. 2015
  • AML treatment strategy based on cytogenetic abnormalities and somatic mutations, IMAI Yoichi, Rinsho Ketsueki, 56(10), 1932-1941, 2015
    DOI
  • Intracellular Reactive Oxygen Species Mark and Influence the Megakaryocyte-Erythrocyte Progenitor Fate of Common Myeloid Progenitors, Akihito Shinohara; Yoichi Imai; Masahiro Nakagawa; Tsuyoshi Takahashi; Motoshi Ichikawa; Mineo Kurokawa, STEM CELLS, 32(2), 548-557, Feb. 2014
    DOI
  • Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source, H. Shiozaki; K. Yoshinaga; T. Kondo; Y. Imai; M. Shiseki; N. Mori; M. Teramura; T. Motoji, BONE MARROW TRANSPLANTATION, 49(1), 102-109, Jan. 2014
    DOI
  • Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma, Tetsuichi Yoshizato; Yasuhito Nannya; Yoichi Imai; Motoshi Ichikawa; Mineo Kurokawa, CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 13(4), 410-416, Aug. 2013
    DOI
  • Successful treatment of secondary NK/T-cell lymphoma of the testis, Takashi Kobayashi; Akira Hangaishi; Go Yamamoto; Akihito Shinohara; Teppei Morikawa; Yutaka Takazawa; Satoshi Ota; Yoichi Imai; Fumihiko Nakamura; Mineo Kurokawa, ANNALS OF HEMATOLOGY, 92(7), 997-998, Jul. 2013
    DOI
  • 原発性骨髄線維症に合併した大量腹水に対して腹腔静脈シャントが著効した1例., 石山みどり; 寺村正尚; 岡村隆光; 志村華絵; 兒玉聖子; 田中紀奈; 三橋健次郎; 風間啓至; 吉永健太郎; 今井陽一; 志関雅幸; 森直樹; 泉二登志子, 東京女子医科大学雑誌, 83(臨増), E594-E598, 2013
  • Regression of Rectal Mucosa-associated Lymphoid Tissue (MALT) Lymphoma after Helicobacter pylori Eradication, Ding Ye; Yoshinaga Kentaro; Maruyama Masataka; Imai Yoichi; Shiseki Masayuki; Mori Naoki; Masuda Akihiro; Teramura Masanao; Motoji Toshiko, Journal of Tokyo Women's Medical College, 83(2), E628-E632, 2013
  • Thrombocytopenia Was Improved by Chemotherapy for Diffuse Large B-cell Lymphoma Attended with Monoclonal Gammopathy and Immune Thrombocytopenia, Watanabe Aya; Imai Yoichi; Shimura Hanae; Tanaka Norina; Mitsuhashi Kenjiro; Kazama Hiroshi; Shiseki Masayuki; Mori Naoki; Teramura Masanao; Motoji Toshiko, Journal of Tokyo Women's Medical College, 83(2), E633-E637, 2013
  • 多発性骨髄腫の治療抵抗性獲得において接着分子が果たす役割., 今井陽一; 泉二登志子; 責任著者, 東京女子医科大学雑誌, 83, E465-E469, 2013
  • がんの最新治療 各論(5)多発性骨髄腫., 今井陽一; 責任著者, 東京女子医科大学雑誌, 83, 160-167, 2013
  • Classification and Chromosomal Studies of Acute Myeloid Leukemia in Adults: Analysis of 300 Patients over the Past 28 Years in a Single Institution of Japan, Okada Michiko; Usami Akemi; Okajima Kaori; Miura Hiroko; Kodama Shoko; Shimura Hanae; Tanaka Norina; Mitsuhashi Kenjiro; Ishiyama Midori; Kazama Hiroshi; Yoshinaga Kentaro; Imai Yoichi; Shiseki Masayuki; Mori Naoki; Teramura Masanao; Motoji Toshiko, Journal of Tokyo Women's Medical College, 83(2), E539-E547, 2013
  • 成人急性骨髄性白血病の成績：単施設における後方視的検討., 田中紀奈; 森直樹; 榎本有希; 渡邉彩; 石森紀子; 丁曄; 志村華絵; 兒玉聖子; 三橋健次郎; 石山みどり; 風間啓至; 吉永健太郎; 今井陽一; 志関雅幸; 山田 修; 寺村正尚; 泉二登志子, 東京女子医科大学雑誌, 83(臨増), E548-E555, 2013
  • 当科での急性リンパ性白血病の治療成績, 志村華絵; 森直樹; 岡田美智子; 榎本有希; 渡邉彩; 石森紀子; 丁曄; 兒玉聖子; 田中紀奈; 三橋健次郎; 石山みどり; 風間啓至; 吉永健太郎; 今井陽一; 志関雅幸; 寺村正尚; 泉二登志子, 東京女子医科大学雑誌, 83(臨増), E556-E562, 2013
  • 濾胞性リンパ腫に対するリツキシマブ併用化学療法の当科における成績., 風間啓至; 寺村正尚; 榎本有希; 渡邉彩; 石森紀子; 丁曄; 志村華絵; 兒玉聖子; 田中紀奈; 三橋健次郎; 石山みどり; 吉永健太郎; 今井陽一; 志関雅幸; 森直樹; 泉二登志子, 東京女子医科大学雑誌, 83(臨増), E563-E568, 2013
  • Usefulness of the Revised International Prognostic Index for Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-based Chemotherapy, Mitsuhashi Kenjiro; Shiseki Masayuki; Enomoto Yuki; Watanabe Aya; Ishimori Noriko; Ding Ye; Shimura Hanae; Kodama Shoko; Tanaka Norina; Ishiyama Midori; Kazama Hiroshi; Yoshinaga Kentaro; Imai Yoichi; Mori Naoki; Teramura Masanao; Motoji Toshiko, Journal of Tokyo Women's Medical College, 83(2), E569-E575, 2013
  • Retrospective Analysis of Hematopoietic Stem Cell Transplants in Tokyo Women's Medical University: A Single Center Experience, Yoshinaga Kentaro; Enomoto Yuki; Watanabe Aya; Ding Ye; Ishimori Noriko; Shimura Hanae; Kodama Shoko; Tanaka Norina; Asano Chihiro; Mitsuhashi Kenjiro; Ishiyama Midori; Kondo Toshiaki; Yasunami Takeshi; Kazama Hiroshi; Okamura Takamitsu; Imai Yoichi; Shiseki Masayuki; Mori Naoki; Yamada Osamu; Teramura Masanao; Masuda Michihiko; Motoji Toshiko, Journal of Tokyo Women's Medical College, 83(2), E585-E593, 2013
  • Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis, Hanae Shimura; Yoichi Imai; Masahiro Ieko; Masayuki Shiseki; Naoki Mori; Masanao Teramura; Toshiko Motoji, ANNALS OF HEMATOLOGY, 92(1), 143-144, Jan. 2013
    DOI
  • [Long-term remission after nonmyeloablative allogeneic bone marrow transplantation in a relapsed Hodgkin lymphoma patient with CNS involvement]., Hanae Shimura; Yoichi Imai; Midori Ishiyama; Kentaro Yoshinaga; Masayuki Shiseki; Naoki Mori; Masanao Teramura; Toshiko Motoji, [Rinsho ketsueki] The Japanese journal of clinical hematology, 53(12), 1991-6, Dec. 2012
  • Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy, Kenjiro Mitsuhashi; Midori Ishiyama; Yoichi Imai; Masayuki Shiseki; Naoki Mori; Masanao Teramura; Akiyoshi Seshimo; Toshiko Motoji, BRITISH JOURNAL OF HAEMATOLOGY, 158(6), 798-800, Sep. 2012
    DOI
  • Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation, Mayumi Yoshimi; Susumu Goyama; Masahito Kawazu; Masahiro Nakagawa; Motoshi Ichikawa; Yoichi Imai; Keiki Kumano; Takashi Asai; James C. Mulloy; Andrew S. Kraft; Tsuyoshi Takahashi; Naoki Shirafuji; Mineo Kurokawa, EUROPEAN JOURNAL OF IMMUNOLOGY, 42(4), 1044-1050, Apr. 2012
    DOI
  • The effect of iron overload and chelation on erythroid differentiation, Kazuki Taoka; Keiki Kumano; Fumihiko Nakamura; Masataka Hosoi; Susumu Goyama; Yoichi Imai; Akira Hangaishi; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 95(2), 149-159, Feb. 2012
    DOI
  • 骨髄破壊的同種骨髄移植後に長期寛解を維持している中枢神経浸潤を合併した再発Hodgkinリンパ腫., 志村華絵; 今井陽一; 石山みどり; 吉永健太郎; 志関雅幸; 森直樹; 寺村正尚; 泉二登志子; 責任著者, 臨床血液, 53, 1991-1996, 2012
  • AML1/RUNX1 functions as a cytoplasmic attenuator of NF-kappa B signaling in the repression of myeloid tumors, Masahiro Nakagawa; Munetake Shimabe; Naoko Watanabe-Okochi; Shunya Arai; Akihide Yoshimi; Akihito Shinohara; Nahoko Nishimoto; Keisuke Kataoka; Tomohiko Sato; Keiki Kumano; Yasuhito Nannya; Motoshi Ichikawa; Yoichi Imai; Mineo Kurokawa, BLOOD, 118(25), 6626-6637, Dec. 2011
    DOI
  • Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity, Keisuke Kataoka; Tomohiko Sato; Akihide Yoshimi; Susumu Goyama; Takako Tsuruta; Hiroshi Kobayashi; Munetake Shimabe; Shunya Arai; Masahiro Nakagawa; Yoichi Imai; Keiki Kumano; Katsuyoshi Kumagai; Naoto Kubota; Takashi Kadowaki; Mineo Kurokawa, JOURNAL OF EXPERIMENTAL MEDICINE, 208(12), 2402-2415, Nov. 2011
    DOI
  • Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19(ARF), Nahoko Nishimoto; Shunya Arai; Motoshi Ichikawa; Masahiro Nakagawa; Susumu Goyama; Keiki Kumano; Tsuyoshi Takahashi; Yasuhiko Kamikubo; Yoichi Imai; Mineo Kurokawa, BLOOD, 118(9), 2541-2550, Sep. 2011
    DOI
  • Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells, Shunya Arai; Akihide Yoshimi; Munetake Shimabe; Motoshi Ichikawa; Masahiro Nakagawa; Yoichi Imai; Susumu Goyama; Mineo Kurokawa, BLOOD, 117(23), 6304-6314, Jun. 2011
    DOI
  • The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk, Yasuhito Nannya; Keisuke Kataoka; Akira Hangaishi; Yoichi Imai; Tsuyoshi Takahashi; Mineo Kurokawa, TRANSPLANT INTERNATIONAL, 24(5), 469-476, May 2011
    DOI
  • Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia, Tetsuichi Yoshizato; Yasuhito Nannya; Yumiko Yoshiki; Fumihiko Nakamura; Yoichi Imai; Motoshi Ichikawa; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(3), 400-402, Mar. 2011
    DOI
  • Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins, Akihide Yoshimi; Susumu Goyama; Naoko Watanabe-Okochi; Yumiko Yoshiki; Yasuhito Nannya; Eriko Nitta; Shunya Arai; Tomohiko Sato; Munetake Shimabe; Masahiro Nakagawa; Yoichi Imai; Toshio Kitamura; Mineo Kurokawa, BLOOD, 117(13), 3617-3628, Mar. 2011
    DOI
  • Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma, Chiharu I. Kobayashi; Go Yamamoto; Akimasa Hayashi; Satoshi Ota; Yoichi Imai; Masashi Fukayama; Mineo Kurokawa, ANNALS OF HEMATOLOGY, 90(2), 225-226, Feb. 2011
    DOI
  • 悪性リンパ腫化学療法後に左腎病変内へ出血し仮性動脈瘤を形成した1例, 中村 順子; 赤羽 正章; 早川 弥生; 今井 陽一; 前田 恵理子; 佐藤 次郎; 稲生 信一; 小松 秀平; 吉岡 直紀; 大友 邦, Japanese Journal of Radiology, 29(Suppl.I), 17-17, Jan. 2011
  • Concurrent development of "Burkitt-like" lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin, Hiroshi Kobayashi; Motoshi Ichikawa; Akira Hangaishi; Yoichi Imai; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 93(1), 112-117, Jan. 2011
    DOI
  • A Case of Myeloid Sarcoma with Correlation to JAK2V617F Mutation, Complicated by Myelofibrosis and Secondary Acute Myeloid Leukemia, Yumiko Yoshiki; Takashi Asai; Motoshi Ichikawa; Akira Hangaishi; Satoshi Ota; Yoichi Imai; Tsuyoshi Takahashi; Mineo Kurokawa, INTERNAL MEDICINE, 50(21), 2649-2652, 2011
    DOI
  • Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT, K. Ueda; T. Watadani; E. Maeda; S. Ota; K. Kataoka; S. Seo; K. Kumano; A. Hangaishi; T. Takahashi; Y. Imai; K. Ohtomo; M. Fukayama; Y. Nannya; M. Kurokawa, BONE MARROW TRANSPLANTATION, 45(12), 1719-1727, Dec. 2010
    DOI
  • A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period, Masataka Hosoi; Motoshi Ichikawa; Yoichi Imai; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 92(4), 667-668, Nov. 2010
    DOI
  • CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement, Hiroki Asano; Yoichi Imai; Satoshi Ota; Go Yamamoto; Tsuyoshi Takahashi; Masashi Fukayama; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 92(3), 550-552, Oct. 2010
    DOI
  • IgG-associated immune thrombocytopenia in Waldenstrom macroglobulinemia, Kumi Nakazaki; Akira Hangaishi; Fumihiko Nakamura; Masataka Hosoi; Yoichi Imai; Tsuyoshi Takahashi; Yasuhito Nannya; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 92(2), 360-363, Sep. 2010
    DOI
  • Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature, Keisuke Kataoka; Sachiko Seo; Yasuhiko Sugawara; Satoshi Ota; Yoichi Imai; Tsuyoshi Takahashi; Masashi Fukayama; Norihiro Kokudo; Mineo Kurokawa, LEUKEMIA & LYMPHOMA, 51(8), 1494-1501, Aug. 2010
    DOI
  • T cell acute lymphoblastic leukemia arising from familial platelet disorder, Nahoko Nishimoto; Yoichi Imai; Koki Ueda; Masahiro Nakagawa; Akihito Shinohara; Motoshi Ichikawa; Yasuhito Nannya; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 92(1), 194-197, Jul. 2010
    DOI
  • Essential roles of VLA-4 in the hematopoietic system, Yoichi Imai; Motomu Shimaoka; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 91(4), 569-575, May 2010
    DOI
  • High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis, Yuki Kagoya; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 91(2), 326-327, Mar. 2010
    DOI
  • Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma, Masataka Hosoi; Go Yamamoto; Yoichi Imai; Mineo Kurokawa, ANNALS OF HEMATOLOGY, 89(2), 207-208, Feb. 2010
    DOI
  • Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes, Eun Jeong Park; Antonio Peixoto; Yoichi Imai; Ahmad Goodarzi; Guiying Cheng; Christopher V. Carman; Ulrich H. von Andrian; Motomu Shimaoka, BLOOD, 115(8), 1572-1581, Feb. 2010
    DOI
  • Efficacy and Safety of Modified Rituximab-ESHAP Therapy for Relapsed/Refractory B-Cell Lymphoma, K. Ueda; Y. Nannya; T. Asai; G. Yamamoto; A. Hangaishi; T. Takahashi; Y. Imai; M. Kurokawa, JOURNAL OF CHEMOTHERAPY, 22(1), 54-57, Feb. 2010
  • A case report of non-traumatic renal artery pseudoaneurysm due to chemotherapy for diffuse large B-cell lymphoma, Yosuke Masamoto; Yoichi Imai; Sachiko Seo; Masaaki Akahane; Mineo Kurokawa, ANNALS OF HEMATOLOGY, 89(1), 107-108, Jan. 2010
    DOI
  • HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases, Tsuyoshi Takahashi; Akira Hangaishi; Go Yamamoto; Motoshi Ichikawa; Yoichi Imai; Mineo Kurokawa, AMERICAN JOURNAL OF HEMATOLOGY, 85(1), 85-87, Jan. 2010
    DOI
  • EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization, S. Goyama; E. Nitta; T. Yoshino; S. Kako; N. Watanabe-Okochi; M. Shimabe; Y. Imai; K. Takahashi; M. Kurokawa, LEUKEMIA, 24(1), 81-88, Jan. 2010
    DOI
  • Chronic myelomonocytic leukemia presenting severe uterine hemorrhage due to uterine infiltration of leukemic cells and early-stage endometrial adenocarcinoma, Akihide Yoshimi; Takashi Asai; Daichi Maeda; Akira Hangaishi; Takashi Sakatani; Tsuyoshi Takahashi; Yoichi Imai; Masashi Fukayama; Mineo Kurokawa, ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 280(6), 1077-1078, Dec. 2009
    DOI
  • Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells, M. Shimabe; S. Goyama; N. Watanabe-Okochi; A. Yoshimi; M. Ichikawa; Y. Imai; M. Kurokawa, ONCOGENE, 28(49), 4364-4374, Dec. 2009
    DOI
  • Interstitial pneumonia associated with progression of myelodysplastic syndrome, Keisuke Kataoka; Motoshi Ichikawa; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 89(5), 718-719, Jun. 2009
    DOI
  • Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders, Koki Ueda; Yasuhito Nannya; Keiki Kumano; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 89(5), 592-599, Jun. 2009
    DOI
  • Successful Hematopoietic Stem Cell Transplantation from an HLA-Identical Sibling in a Patient with Aplastic Anemia after HLA-Haploidentical Living-Related Liver Transplantation for Fulminant Hepatitis, Akihide Yoshimi; Yasuhito Nannya; Kouki Ueda; Daiki Asano; Go Yamamoto; Kumano Keiki; Akira Hangaishi; Yuichi Matsui; Tsuyoshi Takahashi; Yoichi Imai; Yasuhiko Sugawara; Norihiro Kokudo; Mineo Kurokawa, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(3), 389-390, Mar. 2009
    DOI
  • Acute eosinophilic pneumonia is a non-infectious lung complication after allogeneic hematopoietic stem cell transplantation, Mayumi Yoshimi; Yasuhito Nannya; Takuro Watanabe; Takashi Asai; Motoshi Ichikawa; Go Yamamoto; Keiki Kumano; Akira Hangaishi; Yoichi Imai; Tsuyoshi Takahashi; Shigeru Chiba; Mineo Kurokawa, INTERNATIONAL JOURNAL OF HEMATOLOGY, 89(2), 244-248, Mar. 2009
    DOI
  • 化学療法に伴う好中球減少時の発熱に対するmoxifloxacin(1日1回)の予防投与の効果と安全性の検討, 吉識 由実子; 篠原 明仁; 南谷 泰仁; 正本 庸介; 高橋 強志; 今井 陽一; 半下石 明; 黒川 峰夫, 日本内科学会雑誌, 98(Suppl.), 202-202, Feb. 2009
  • Influence of Pretransplantation Serum Ferritin on Nonrelapse Mortality after Myeloablative and Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Keisuke Kataoka; Yasuhito Nannya; Akira Hangaishi; Yoichi Imai; Shigeru Chiba; Tsuyoshi Takahashi; Mineo Kurokawa, BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 15(2), 195-204, Feb. 2009
    DOI
  • Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates alpha(4) integrins, Yoichi Imai; Eun Jeong Park; Dan Peer; Antonio Peixoto; Guiying Cheng; Ulrich H. von Andrian; Christopher V. Carman; Motomu Shimaoka, BLOOD, 112(13), 5007-5015, Dec. 2008
    DOI
  • A Non-Canonical Function of Zebrafish Telomerase Reverse Transcriptase Is Required for Developmental Hematopoiesis, Shintaro Imamura; Junzo Uchiyama; Eriko Koshimizu; Jun-ichi Hanai; Christina Raftopoulou; Ryan D. Murphey; Peter E. Bayliss; Yoichi Imai; Caroline Erter Burns; Kenkichi Masutomi; Sarantis Gagos; Leonard I. Zon; Thomas M. Roberts; Shuji Kishi, PLOS ONE, 3(10), e3364, Oct. 2008
    DOI
  • 遺伝子改変マウスによる恒常的活性化型α4インテグリンの機能解析, 今井 陽一; 島岡 要, 臨床血液, 48(9), 996-996, Sep. 2007
  • Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies, Kumi Oshima; Yoshinobu Kanda; Fumio Nakahara; Eriko Shoda; Takahiro Suzuki; Yoichi Imai; Takuro Watanabe; Takashi Asai; Koji Izutsu; Seishi Ogawa; Toru Motokura; Shigeru Chiba; Mineo Kurokawa, AMERICAN JOURNAL OF HEMATOLOGY, 81(11), 875-879, Nov. 2006
    DOI
  • Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP, E Nitta; K Izutsu; Y Yamaguchi; Y Imai; S Ogawa; S Chiba; M Kurokawa; H Hirai, ONCOGENE, 24(40), 6165-6173, Sep. 2005
    DOI
  • Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase, Y Komeno; M Kurokawa; Y Imai; M Takeshita; T Matsumura; K Kubo; T Yoshino; U Nishiyama; T Kuwaki; K Kubo; T Osawa; S Ogawa; S Chiba; A Miwa; H Hirai, LEUKEMIA, 19(6), 930-935, Jun. 2005
    DOI
  • Notch1 oncoprotein antagonizes TGF-beta/Smad-mediated cell growth suppression via sequestration of coactivator p300, S Masuda; K Kumano; K Shimizu; Y Imai; M Kurokawa; S Ogawa; M Miyagishi; K Taira; H Hirai; S Chiba, CANCER SCIENCE, 96(5), 274-282, May 2005
    DOI
  • The transcriptionafly active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region, S Goyama; Y Yamaguchi; Y Imai; M Kawazu; M Nakagawa; T Asai; K Kumano; K Mitani; S Ogawa; S Chiba; M Kurokawa; H Hirai, BLOOD, 104(12), 3558-3564, Dec. 2004
    DOI
  • Clinical significance of peripheral blood erythroblastosis after hematopoietic stem cell transplantation, S Goyama; Y Kanda; Y Nannya; S Ogawa; Y Asano-Moki; N Ogawa; M Nakagawa; M Sakata-Yanagimoto; M Kawazu; Y Komeno; Y Imai; A Hangaishi; M Kurokawa; S Tsujino; K Aoki; S Chiba; T Motokura; H Hirai, LEUKEMIA & LYMPHOMA, 45(12), 2439-2443, Dec. 2004
    DOI
  • Predictors for severe cardiac complications after hematopoietic stem cell transplantation, M Sakata-Yanagimoto; Y Kanda; M Nakagawa; Y Asano-Mori; K Kandabashi; K Izutsu; Y Imai; A Hangaishi; M Kurokawa; S Tsujino; S Ogawa; S Chiba; T Motokura; H Hirai, BONE MARROW TRANSPLANTATION, 33(10), 1043-1047, May 2004
    DOI
  • Functional analysis of a dominant-negative Delta ETS TEL/ETV6 isoform, A Sasaki; Y Nakamura; K Maki; K Waga; F Nakamura; H Arai; Y Imai; H Hirai; K Mitani, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 317(4), 1128-1137, May 2004
    DOI
  • TdT陽性腸管T細胞リンパ腫の1例, 大島 久美; 鈴木 美穂; 伊豆津 宏二; 正田 絵里子; 今井 陽一; 半下石 明; 神田 善伸; 辻野 志穂; 黒川 峰夫; 千葉 滋; 本倉 徹; 永井 良三; 吉田 朗彦; 竹内 賢吾; 仁木 利郎, 臨床血液, 45(4), 329-329, Apr. 2004
  • AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues, Y Yamaguchi; M Kurokawa; Y Imai; K Izutsu; T Asai; M Ichikawa; G Yamamoto; E Nitta; T Yamagata; K Sasaki; K Mitani; S Ogawa; S Chiba; H Hirai, JOURNAL OF BIOLOGICAL CHEMISTRY, 279(15), 15630-15638, Apr. 2004
    DOI
  • Leukemia-related transcription factor TEL is negatively regulated through extracellular signal-regulated kinase-induced phosphorylation, K Maki; H Arai; K Waga; K Sasaki; F Nakamura; Y Imai; M Kurokawa; H Hirai; K Mitani, MOLECULAR AND CELLULAR BIOLOGY, 24(8), 3227-3237, Apr. 2004
    DOI
  • Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion, N Ogawa; Y Kanda; M Matsubara; Y Asano; M Nakagawa; M Sakata-Yanagimoto; K Kandabashi; K Izutsu; Y Imai; A Hangaishi; M Kurokawa; S Tsujino; S Ogawa; K Aoki; S Chiba; T Motokura; H Hirai, BONE MARROW TRANSPLANTATION, 33(5), 549-552, Mar. 2004
    DOI
  • The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1, Y Imai; M Kurokawa; Y Yamaguchi; K Izutsu; E Nitta; K Mitani; M Satake; T Noda; Y Ito; H Hirai, MOLECULAR AND CELLULAR BIOLOGY, 24(3), 1033-1043, Feb. 2004
    DOI
  • Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway from activin A in hematopoietic cells, S Chiba; K Takeshita; Y Imai; K Kumano; M Kurokawa; S Masuda; K Shimizu; S Nakamura; FH Ruddle; H Hirai, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 100(26), 15577-15582, Dec. 2003
    DOI
  • Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation, Y Asano; Y Kanda; N Ogawa; M Sakata-Yanagimoto; M Nakagawa; M Kawazu; S Goyama; K Kandabashi; K Izutsu; Y Imai; A Hangaishi; M Kurokawa; S Tsujino; S Ogawa; K Aoki; S Chiba; T Motokura; H Hirai, BONE MARROW TRANSPLANTATION, 32(12), 1175-1179, Dec. 2003
    DOI
  • Identification of a novel fusion gene, TTL, fused to ETV6 in acute lymphoblastic leukemia with t(12;13)(p13;q14), and its implication in leukemogenesis, Y Qiao; S Ogawa; A Hangaishi; K Yuji; K Izutsu; A Kunisato; Y Imai; L Wang; N Hosoya; Y Nannya; Y Sato; K Maki; K Mitani; H Hirai, LEUKEMIA, 17(6), 1112-1120, Jun. 2003
    DOI
  • Should young patients with e19a2 type BCR/ABL rearrangement undergo stem cell transplantation?, F Nakamura; S Ogawa; K Izutsu; Y Imai; K Maki; T Yamagata; K Mitani; H Hirai, LEUKEMIA & LYMPHOMA, 44(2), 381-382, 2003
    DOI
  • Functional regulation of TEL by p38-induced phosphorylation, H Arai; K Maki; K Waga; K Sasaki; Y Nakamura; Y Imai; M Kurokawa; H Hirai; K Mitani, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 299(1), 116-125, Nov. 2002
  • To the editor: Mutations of Chk2 in primary hematopoietic neoplasms, A Hangaishi; S Ogawa; Y Qiao; LL Wang; N Hosoya; K Yuji; Y Imai; K Takeuchi; S Miyawaki; H Hirai, BLOOD, 99(8), 3075-3077, Apr. 2002
  • The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP, K Izutsu; M Kurokawa; Y Imai; M Ichikawa; T Asai; K Maki; K Mitani; H Hirai, ONCOGENE, 21(17), 2695-2703, Apr. 2002
  • Mutational analyses of the AML1 gene in patients with myelodysplastic syndrome, Y Imai; M Kurokawa; K Izutsu; A Hangaishi; K Maki; S Ogawa; S Chiba; K Mitani; H Hirai, LEUKEMIA & LYMPHOMA, 43(3), 617-621, Mar. 2002
    DOI
  • 骨髄異形成症候群におけるAML1遺伝子異常の解析., 今井陽一; 責任著者, 臨床血液, 43, 139-145, 2002
  • The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling, K Izutsu; M Kurokawa; Y Imai; K Maki; K Mitani; H Hirai, BLOOD, 97(9), 2815-2822, May 2001
  • Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis, Y Imai; M Kurokawa; K Izutsu; A Hangaishi; K Maki; S Ogawa; S Chiba; K Mitani; H Hirai, ONCOGENE, 20(1), 88-96, Jan. 2001
  • Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis, Y Imai; M Kurokawa; K Izutsu; A Hangaishi; K Takeuchi; K Maki; S Ogawa; S Chiba; K Mitani; H Hirai, BLOOD, 96(9), 3154-3160, Nov. 2000
  • Hepatocellular carcinoma followed by Waldenstrom's macroglobulinemia: A case report, K Hasegawa; K Kubota; H Hirai; Y Imai; Y Midorikawa; M Makuuchi, HEPATO-GASTROENTEROLOGY, 47(33), 842-845, May 2000
  • The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells, M Kurokawa; K Mitani; Y Imai; S Ogawa; Y Yazaki; H Hirai, BLOOD, 92(11), 4003-4012, Dec. 1998
  • TLE, the human homolog of Groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation, Y Imai; M Kurokawa; K Tanaka; AD Friedman; S Ogawa; K Mitani; Y Yazaki; H Hirai, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 252(3), 582-589, Nov. 1998
  • The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2 beta(CBF beta) in the nucleus more efficiently than wild-type AML1, K Tanaka; T Tanaka; M Kurokawa; Y Imai; S Ogawa; K Mitani; Y Yazaki; H Hirai, BLOOD, 91(5), 1688-1699, Mar. 1998
  • Bronchiolitis obliterans organizing pneumonia after syngeneic bone marrow transplantation for acute lymphoblastic leukemia, Y Kanada; T Takahashi; Y Imai; K Miyagawa; N Ohishi; T Oka; S Chiba; H Hirai; Y Yazaki, BONE MARROW TRANSPLANTATION, 19(12), 1251-1253, Jun. 1997
  • The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability, T Tanaka; M Kurokawa; K Ueki; K Tanaka; Y Imai; K Mitani; K Okazaki; N Sagata; Y Yazaki; Y Shibata; T Kadowaki; H Hirai, MOLECULAR AND CELLULAR BIOLOGY, 16(7), 3967-3979, Jul. 1996
  • Current and Future PET Imaging in Multiple Myeloma., Ishibashi M; Takahashi M; Yamaya T; Imai Y, Life, 13, 1701-1701, Aug. 2023
  • RUNX1-Survivin Axis Is a Novel Therapeutic Target for Malignant Rhabdoid Tumors., Masamitsu Mikami; Tatsuya Masuda; Takuya Kanatani; Mina Noura; Katsutsugu Umeda; Hidefumi Hiramatsu; Hirohito Kubota; Tomoo Daifu; Atsushi Iwai; Etsuko Yamamoto Hattori; Kana Furuichi; Saho Takasaki; Sunao Tanaka; Yasuzumi Matsui; Hidemasa Matsuo; Masahiro Hirata; Tatsuki R Kataoka; Tatsutoshi Nakahata; Yasumichi Kuwahara; Tomoko Iehara; Hajime Hosoi; Yoichi Imai; Junko Takita; Hiroshi Sugiyama; Souichi Adachi; Yasuhiko Kamikubo, Molecules and cells, 45(12), 886-895, 31 Dec. 2022
    DOI
  • 全身性肥満細胞症に合併した急性骨髄性白血病の1例, 大貝 明日香; 川俣 豊隆; 佐藤 亜紀; 横山 和明; 小川 弥穂; 櫻井 健一; 磯部 優理; 加藤 せい子; 小沼 貴晶; 安井 寛; 今井 陽一; 高橋 聡; 大田 泰徳; 南谷 泰仁, 臨床血液, 63(10), 1461-1461, Oct. 2022
  • Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for NK-cell therapy in acute myeloid leukemia, Yuta Kaito; Emi Sugimoto; Fumi Nakamura; Yutaka Tsukune; Makoto Sasaki; Shunsuke Yui; Hiroki Yamaguchi; Susumu Goyama; Yasuhito Nannya; Kinuko Mitani; Hideto Tamura; Yoichi Imai, Haematologica, Sep. 2023
    DOI
  • ロミプロスチムとビンクリスチン、リツキシマブ、プレドニンの併用が奏効したDLBCL治療後の血小板減少症の1例, 榎本 有希; 志村 華絵; 今井 陽一; 志関 雅幸; 森 直樹; 田中 淳司, 臨床血液, 55(7), 824-824, Jul. 2014
  • 低悪性度B細胞性リンパ腫に対するベンダムスチン療法におけるサイトメガロウイルス再活性化の検討, 石森 紀子; 今井 陽一; 榎本 有希; 渡邉 彩; 兒玉 聖子; 志村 華絵; 田中 紀奈; 浅野 千尋; 三橋 健次郎; 石山 みどり; 風間 啓至; 吉永 健太郎; 志関 雅幸; 森 直樹; 増田 道彦; 寺村 正尚; 泉二 登志子, 臨床血液, 54(9), 1154-1154, Sep. 2013
  • Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System, Keisuke Kataoka; Tomohiko Sato; Akihide Yoshimi; Susumu Goyama; Takako Tsuruta; Shunya Arai; Yoichi Imai; Katsuyoshi Kumagai; Naoto Kubota; Takashi Kadowaki; Mineo Kurokawa, Blood, 116(21), 838-838, 19 Nov. 2010
    DOI
  • Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia., Sugimoto E, Li J, Hayashi Y, Iida K, Asada S, Fukushima T, Tamura M, Shikata S, Zhang W, Yamamoto K, Kawabata KC, Kawase T, Saito T, Yoshida T, Yamazaki S, Kaito Y, Imai Y, Denda T, Ota Y, Fukuyama T, Tanaka Y, Enomoto Y, Kitamura T, Goyama S., Communications biology, 6, 1294-1294, Jun. 2023
    DOI
  • Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia., Sugimoto E, Li J, Hayashi Y, Iida K, Asada S, Fukushima T, Tamura M, Shikata S, Zhang W, Yamamoto K, Kawabata KC, Kawase T, Saito T, Yoshida T, Yamazaki S, Kaito Y, Imai Y, Denda T, Ota Y, Fukuyama T, Tanaka Y, Enomoto Y, Kitamura T, Goyama S., Communications biology, 6, 1294-1294, Jun. 2023
    DOI
  • A whole gamma imaging prototype for higher quantitative imaging of 89Zr-labeled antibodies in a tumor mouse model., Takyu S.; Tashima H.; Takahashi M.; Yoshida E.; Wakizaka H.; Obata F.; Akamatsu G.; Nagatsu K.; Sugyo A.; Sudo H.; Tsuji AB; Ishibashi M.; Imai Y.; Parodi K.; Yamaya T., Physics in Medicine and Biology, 2025
  • SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation., Chang Y-H; Yamamoto K; Fujino T; Wang T-W; Sugimoto E; Zhang W; Yabushita T; Suzaki K; Pietsch EC; Weir BA; Crescenzo R; Cowley GS; Attar R; Philippar U; Wunderlich M; Mizukawa B; Zheng Y; Enomoto Y; Imai Y; Kitamura T; Goyama S, Cell Reports, Aug. 2024
  • Hyperactive Natural Killer cells in Rag2 knockout mice inhibit the development of acute myeloid leukemia, Emi Sugimoto; Jingmei Li; Yasutaka Hayashi; Kohei Iida; Shuhei Asada; Tsuyoshi Fukushima; Moe Tamura; Shiori Shikata; Wenyu Zhang; Keita Yamamoto; Kimihito Cojin Kawabata; Tatsuya Kawase; Takeshi Saito; Taku Yoshida; Satoshi Yamazaki; Yuta Kaito; Yoichi Imai; Tamami Denda; Yasunori Ota; Tomofusa Fukuyama; Yosuke Tanaka; Yutaka Enomoto; Toshio Kitamura; Susumu Goyama, Communications Biology, 6(1), 21 Dec. 2023
    DOI
  • 亜ヒ酸抵抗性でAm80投与中に再発した急性前骨髄球性白血病に対し,減量GO投与が奏効した1例, 五十嵐 美歌; 中村 文美; 五十嵐 美咲; 高橋 渉; 新井 ほのか; 半田 智幸; 仲村 祐子; 中村 由香; 瀬尾 幸子; 佐々木 光; 今井 陽一; 三谷 絹子, 臨床血液, 64(10), 1349-1349, Oct. 2023
  • 悪性リンパ腫の中枢神経系再発患者に対するR-MPV療法の治療成績, 五十嵐 美咲; 中村 文美; 高橋 渉; 礒 桐子; 新井 ほのか; 鶴見 茂治; 半田 智幸; 湯浅 博美; 仲村 祐子; 中村 由香; 瀬尾 幸子; 佐々木 光; 今井 陽一; 三谷 絹子, 日本血液学会学術集会, 85回, 561-561, Oct. 2023
  • 併発AMLに対して同種造血幹細胞移植を施行したMGUSの1例(A case of MGUS who underwent allogeneic HCT for intercurrent AML), 千金楽 涼水; 瀬尾 幸子; 半田 智幸; 中村 由香; 高橋 渉; 中村 文美; 新井 ほのか; 佐々木 光; 今井 陽一; 三谷 絹子, International Journal of Myeloma, 13(3), 155-155, May 2023
  • AZA+Ven療法でブリッジング後CBTを施行した寛解導入不応AML with inv(3), 五十嵐 美咲; 高橋 渉; 中村 文美; 湯浅 博美; 礒 桐子; 鶴見 茂治; 新井 ほのか; 半田 智幸; 仲村 祐子; 中村 由香; 瀬尾 幸子; 佐々木 光; 今井 陽一; 三谷 絹子, 臨床血液, 64(4), 311-312, Apr. 2023
  • 消化器がん・血液がん化学療法患者における血清チアミン値と精神神経症状に関する研究, 飯村 洋平; 黒川 友博; 安藤 匠平; 川俣 豊隆; 佐藤 亜紀; 横山 和明; 今井 陽一; 釣田 義一郎; 阿彦 友佳; 愛甲 丞; 志田 大; 野島 正寛; 東條 有伸; 杉浦 宗敏; 黒田 誠一郎, 日本癌治療学会学術集会抄録集, 59回, O14-5, Oct. 2021
  • 免疫機能異常者のSARS-CoV-2抗体陽性率の経時的変化について, 古賀 道子; 齋藤 真; 堤 武也; 四柳 宏; 山吉 誠也; 石坂 彩; 水谷 壮利; 永井 悦子; 西山 直子; 久保田 めぐみ; 久保 奈津子; 萩原 小夏; 小西 隆介; 今井 陽一; 安井 寛; 川俣 豊隆; 山本 元久; 長村 登紀子; 河岡 義裕, 日本感染症学会東日本地方会学術集会・日本化学療法学会東日本支部総会合同学会プログラム・抄録集, 70回・68回, 181-181, Sep. 2021
  • Correction to: Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities (Annals of Hematology, (2020), 99, 11, (2577-2586), 10.1007/s00277-020-04267-0), Norina Tanaka; Yoichi Imai; Kentaro Yoshinaga; Masayuki Shiseki; Junji Tanaka, Annals of Hematology, 99(11), 2587, 01 Nov. 2020
    DOI
  • 急性混合性白血病に対する末梢血幹細胞移植後に,水痘帯状疱疹ウイルスによる劇症肝炎を発症した1例, 龍野 桂太; 合山 進; 半下石 明; 河津 正人; 今井 陽一; 神田 善伸; 黒川 峰夫; 辻野 志穂; 小川 誠司; 青木 克己; 千葉 滋; 本倉 徹; 平井 久丸; 牛久 哲男; 深山 正久, 臨床血液, 44(6), 414-414, Jun. 2003
    Review paper
  • 連載　血液専門医講座　血液専門医のための模擬テスト34―解答と解説―, Yoichi Imai, 血液内科, 86(1), 147-149, Jan. 2023
  • 特集：多発性骨髄腫update IV.診断と治療　治療の進歩　多発性骨髄腫に対する抗体医薬の意義と展望, Yoichi Imai, 日本臨床, 81(6), 915-921, Jun. 2023
  • Current and Future PET Imaging in Multiple Myeloma., Ishibashi M, Takahashi M, Yamaya T, Imai Y., Life, 13(8), 1701-1701, Aug. 2023
    DOI
  • Progress of therapeutic antibodies in the treatment of patients with multiple myeloma and possible impacts of antibodies on the evaluation of response to the treatment., Imai Y, Handa T, Mitani K., Dokkyo Medical Journal, 2024
  • 特集　骨髄腫と類縁疾患の検査学　分子標的薬の進歩と検査への影響と課題, Imai Y, 臨床検査, 68, 872-877, Jul. 2024
  • Novel treatment strategies for hematological malignancies in the immunotherapy era, Yoichi Imai, International Journal of Hematology, 120(1), 3-5, 11 Jun. 2024
    DOI
  • Evolution of natural killer cell-targeted therapy for acute myeloid leukemia, Yuta Kaito; Yoichi Imai, International Journal of Hematology, 120(1), 34-43, 01 May 2024
    DOI
    Case report
  • Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12), Fumi Nakamura; Sachiko Seo; Yasuhito Nannya; Rika Ayabe; Wataru Takahashi; Tomoyuki Handa; Honoka Arai; Hisako Iso; Yuko Nakamura; Yuka Nakamura; Ko Sasaki; Motoshi Ichikawa; Yoichi Imai; Seishi Ogawa; Kinuko Mitani, INTERNATIONAL JOURNAL OF HEMATOLOGY, Mar. 2023
    DOI
  • Progression to B acute lymphoblastic leukemia in 8p11 myeloproliferative syndrome with t(6;8)(q27;p12)., Nakamura F, Seo S, Nannya Y, Ayabe R, Takahashi W, Handa T, Arai H, Iso H, Nakamura Y, Nakamura Y, Sasaki K, Ichikawa M, Imai Y, Ogawa S, Mitani K., Sep. 2023
  • EBV関連血球貪食症候群の加療27年後に節外性NK/T細胞リンパ腫を発症し,ハプロ移植を施行した1例, 野村 侑里; 中村 文美; 五十嵐 美咲; 湯浅 博美; 高橋 渉; 新井 ほのか; 半田 智幸; 仲村 祐子; 中村 由香; 瀬尾 幸子; 佐々木 光; 今井 陽一; 三谷 絹子, 臨床血液, 65(4), 292-293, Apr. 2024
  • A CML Patient Carrying BCR::ABL1 Splicing Variants Did not Experience Blast Crisis for 15 Years without Responding to Various TKIs, Nakamura Fumi; Sasaki Ko; Nannya Yasuhito; Iso Hisako; Nakamura Yuko; Imai Yoichi; Ogawa Seishi; Mitani Kinuko, Internal Medicine, advpub, 2024
    DOI

MISC

  • 特集 骨髄腫と類縁疾患―全身をみわたす診断・治療 骨髄腫の合併症管理 骨病変の予防と治療, 今井陽一, 内科, 130(4), 771-774, Oct. 2022
  • セル・フリーDNAを用いた多発性骨髄腫の早期再発診断—Feasibility study of circulating cell-free DNA in the peripheral blood plasma of patients with multiple myeloma relapse as diagnostic biomarker, 安井 寛; 小林 真之; 今井 陽一, 血液内科 = Hematology / 血液内科編集委員会 編, 84(1), 112-117, Jan. 2022
  • セル・フリーDNAによる多発性骨髄腫の早期再発診断(Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse), 安井 寛; 小林 真之; 佐藤 広太; 近藤 幹也; 石田 禎夫; 海渡 裕太; 田村 秀人; 半田 寛; 築根 豊; 佐々木 純; 小松 則夫; 田中 紀奈; 田中 淳司; 木崎 昌弘; 川俣 豊隆; 牧山 純也; 横山 和明; 井元 清哉; 東條 有伸; 今井 陽一, International Journal of Myeloma, 11(2), 91-91, May 2021
  • Emergence role of peripheral blood erythroblasts on prognosis after cord blood transplantation, 海渡裕太; 小沼貴晶; 加藤せい子; 磯部優理; 岡部基人; 大岩真希; 今井陽一; 高橋聡; 東條有伸, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021
  • Successful treatment of rectal MALT lymphoma involving anal canal with BR and radiation therapy, 櫻井健一; 川俣豊隆; 梨本淳一郎; 佐藤亜紀; 横山和明; 安井寛; 今井陽一; 東條有伸, 日本血液学会学術集会抄録(Web), 83rd, 2021
  • 未治療多発性骨髄腫に対するキノロン予防投与の意義, 今井 陽一, 血液内科, 81(4), 568-573, Oct. 2020
  • 骨髄腫におけるliquid biopsy, 今井陽一, Current Therapy, 38(6), 119-119, Jun. 2020
  • HDAC阻害薬とAKT阻害薬は多発性骨髄腫に対して増殖を抑制し腫瘍免疫を賦活化する, 平野光人; 今井陽一; 村山貴彦; 佐藤広太; 山本淳一; 伊藤拓水; 二見宗孔; 二見宗孔; 李政樹; 安井寛; 安井寛; 上久保靖彦; 後藤典子; 石田禎夫; 飯田真介; 半田宏; 東條有伸; 東條有伸, 日本血液学会学術集会抄録(Web), 82nd, 2020
  • Circulating cell-free DNA in the patient’s peripheral blood plasma is a sensitive biomarker for multiple myeloma relap, 安井寛; 小林真之; 小林真之; 近藤幹也; 石田禎夫; 田村秀人; 半田寛; 佐々木純; 田中紀奈; 田中淳司; 木崎昌弘; 川俣豊隆; 川俣豊隆; 牧山純也; 横山和明; 井元清哉; 井元清哉; 東條有伸; 東條有伸; 今井陽一, 日本癌学会学術総会抄録集(Web), 79th, 2020
  • Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression, Mariko Ishibashi; Ryosuke Kinoshita; Koiti Inokuchi; Hiroshi Handa; Makoto Sasaki; Norio Komatsu; Yoichi Imai; Norina Hiroike; Junji Tanaka; Sakae Tanosaki; Shigeki Ito; Mika Sunakawa; Toshio Asayama; Yasuko Kuribayashi-hamada; Rimpei Morita; Hideto Tamura, BLOOD, 134, Nov. 2019
    DOI
  • 多発性骨髄腫における治療抵抗性バイオマーカーの探索(Establishment of diagnostic biomarkers for relapsed refractory multiple myeloma), 小林 真之; 安井 寛; 佐藤 広太; 石田 禎夫; 田村 秀人; 半田 寛; 佐々木 純; 川俣 豊隆; 牧山 純也; 横山 和明; 東條 有伸; 今井 陽一, 日本癌学会総会記事, 78回, P-1356, Sep. 2019
  • ホジキンリンパ腫に合併した多発性骨髄腫の1例, 安藤 匠平; 横山 和明; 内田 三四郎; 牧山 純也; 川俣 豊隆; 安井 寛; 大田 泰徳; 今井 陽一; 東條 有伸, 臨床血液, 60(5), 529-529, May 2019
  • 多発性骨髄腫治療抵抗性のバイオマーカーの探索(Establishment of diagnostic biomarkers for the relapsed/refractory multiple myeloma in patients treated with lenalidomide-based therapies), 小林 真之; 安井 寛; 佐藤 広太; 石田 禎夫; 田村 秀人; 半田 寛; 佐々木 純; 川俣 豊隆; 牧山 純也; 横山 和明; 東條 有伸; 今井 陽一, International Journal of Myeloma, 9(1), 103-103, May 2019
  • 実臨床における再発・難治性骨髄腫患者に対するERd療法の効果(Efficacy of elotuzumab plus lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma in the real-world practice setting), 添田 沙織; 山下 卓也; 磯田 淳; 鈴木 一史; 木口 亨; 田中 紀奈; 田中 淳司; 佐々木 純; 小松 則夫; 安井 寛; 今井 陽一; 石橋 真理子; 田村 秀人, International Journal of Myeloma, 9(1), 146-146, May 2019
  • 血清KL-6値は多発性骨髄腫の予後予測因子となりうる(KL-6 may be an excellent predictor of prognosis in multiple myeloma), 砂川 実香; 石橋 真理子; 海渡 裕太; 木下 量介; 朝山 敏夫; 守屋 慶一; 半田 寛; 佐々木 純; 今井 陽一; 田中 紀奈; 伊藤 薫樹; 田野崎 栄; 田中 淳司; 小松 則夫; 猪口 孝一; 田村 秀人, International Journal of Myeloma, 9(1), 86-86, May 2019
  • 実臨床における再発・難治性骨髄腫患者に対するERd療法の効果(Efficacy of elotuzumab plus lenalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma in the real-world practice setting), 添田 沙織; 山下 卓也; 磯田 淳; 鈴木 一史; 木口 亨; 田中 紀奈; 田中 淳司; 佐々木 純; 小松 則夫; 安井 寛; 今井 陽一; 石橋 真理子; 田村 秀人, International Journal of Myeloma, 9(1), 146-146, May 2019
  • MTX大量療法後のCNS再発リンパ腫に対し,ベンダムスチンが奏効した1例, 内田三四郎; 川俣豊隆; 安藤匠平; 牧山純也; 横山和明; 安井寛; 今井陽一; 東條有伸, 臨床血液, 60(5), 2019
  • 胆嚢病変にて診断確定した中枢神経原発成人発症ランゲルハンス細胞組織球症, 近藤 幹也; 牧山 純也; 安藤 匠平; 水澤 舞; 川俣 豊隆; 横山 和明; 大田 泰徳; 安井 寛; 今井 陽一; 東條 有伸, 臨床血液, 59(11), 2499-2499, Nov. 2018
  • RHOA遺伝子変異の検出が診断および病勢評価に有用であった血管免疫芽球性T細胞リンパ腫(Successful application of RHOA p.G17V status for diagnosis and disease monitoring in a case of AITL), 水澤 舞; 小川 弥穂; 横山 和明; 川俣 豊隆; 安藤 匠平; 近藤 幹也; 武井 智美; 中村 聡介; 伊藤 美香; 遊佐 希; 笠島 理加; 清水 英悟; 牧山 純也; 安井 寛; 山口 類; 井元 清哉; 宮野 悟; 大田 泰徳; 吉川 賢忠; 田中 廣壽; 今井 陽一; 東條 有伸, 臨床血液, 59(9), 1550-1550, Sep. 2018
  • 当院におけるHIV関連リンパ腫14例の臨床病理学的検討(Clinicopathological analysis of 14 cases of HIV associated lymphoma in IMSUT hospital), 安藤 匠平; 牧山 純也; 水澤 舞; 近藤 幹也; 川俣 豊隆; 横山 和明; 鯉渕 智彦; 安井 寛; 大田 泰徳; 今井 陽一; 四柳 宏; 東條 有伸, 臨床血液, 59(9), 1594-1594, Sep. 2018
  • 改訂版国際病期分類ステージIIにおける多発性骨髄腫の予後因子(Prognostic factors for myeloma patients in Revised International Staging System stage II), 木下 量介; 石橋 真理子; 猪口 孝一; 半田 寛; 佐々木 純; 小松 則夫; 今井 陽一; 田中 紀奈; 田中 淳司; 田野崎 栄; 伊藤 薫樹; 磯田 淳; 松本 守生; 小池 道明; 田村 秀人, 臨床血液, 59(9), 1803-1803, Sep. 2018
  • KL-6産生多発性骨髄腫の臨床的特徴およびKL-6の機能解析(KL-6 as a predictor of prognosis and the function of KL-6/MUC1 in multiple myeloma), 砂川 実香; 田村 秀人; 石橋 真理子; 海渡 裕太; 木下 量介; 朝山 敏夫; 守屋 慶一; 半田 寛; 佐々木 純; 今井 陽一; 田中 紀奈; 伊藤 薫樹; 田野崎 栄; 田中 淳司; 小松 則夫; 猪口 孝一, 臨床血液, 59(9), 1671-1671, Sep. 2018
  • 多発性骨髄腫における病期分類と予後因子の検討 KT-MM予後因子解析, 木下 量介; 石橋 真理子; 半田 寛; 佐々木 純; 今井 陽一; 田中 紀奈; 田野崎 栄; 伊藤 薫樹; 磯田 淳; 朝山 敏夫; 猪口 孝一; 小松 則夫; 田中 淳司; 松本 守生; 小池 道明; 田村 秀人, International Journal of Myeloma, 8(2), 136-136, May 2018
  • イマチニブ単剤で速やかに細胞遺伝学的寛解を得たFIP1L1-PDGFRA陽性AMLの1例, 近藤 幹也; 牧山 純也; 安藤 匠平; 水澤 舞; 川俣 豊隆; 横山 和明; 安井 寛; 今井 陽一; 東條 有伸, 臨床血液, 59(5), 612-612, May 2018
  • 湿疹続発性紅皮症を伴った脾辺縁帯リンパ腫の1例, 安藤 匠平; 横山 和明; 水澤 舞; 近藤 幹也; 牧山 純也; 川俣 豊隆; 安井 寛; 今井 陽一; 高橋 聡; 東條 有伸, 臨床血液, 59(5), 620-620, May 2018
  • 再発または難治性成人T細胞白血病・リンパ腫(ATL)に対する当院でのレナリドミド使用経験, 水澤 舞; 牧山 純也; 安藤 匠平; 近藤 幹也; 川俣 豊隆; 横山 和明; 安井 寛; 今井 陽一; 東條 有伸; 内丸 薫, 臨床血液, 59(5), 624-624, May 2018
  • 再発または難治性成人T細胞白血病・リンパ腫(ATL)に対する当院でのレナリドミド使用経験, 水澤 舞; 牧山 純也; 安藤 匠平; 近藤 幹也; 川俣 豊隆; 横山 和明; 安井 寛; 今井 陽一; 東條 有伸; 内丸 薫, 臨床血液, 59(5), 624-624, May 2018
  • Histone Deacetylase Inhibitos with or whitout AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dpendent Cytotoxicity As Well As Apoptosis, Mitsuhito Hirano; Yoichi Imai; Weng-Chit Ung; Kota Sato; Muneyoshi Futami; Arinobu Tojo, Blood, 132, 4435, 2018
  • The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma, Mariko Ishibashi; Hideto Tamura; Toshio Asayama; Yasuko Kuribayashi-Hamada; Asaka Onodera; Keiichi Moriya; Makoto Sasaki; Hiroshi Handa; Yoichi Imai; Norina Tanaka; Junji Tanaka; Sakae Tanosaki; Shigeki Ito; Norio Komatsu; Koiti Inokuchi, BLOOD, 130, Dec. 2017
  • LPLからの形質転換が示唆されたMYD88変異陽性DLBCLの1例, 越智 清純; 横山 和明; 神保 光児; 平野 光人; 湯佐 希; 小川 弥穂; 竹田 玲奈; 武井 智美; 川俣 豊隆; 福山 朋房; 大野 伸広; 高橋 聡; 山口 類; 内丸 薫; 井元 清哉; 古川 洋一; 宮野 悟; 大田 康徳; 安井 寛; 今井 陽一; 東條 有伸, 臨床血液, 58(8), 1080-1080, Aug. 2017
  • モガムリズマブ投与後、難治性口内炎を来たした同種骨髄移植後ATL再発症例, 小川 弥穂; 川俣 豊隆; 神保 光児; 平野 光人; 越智 清純; 横山 和明; 安井 寛; 安 武夫; 大野 伸広; 今井 陽一; 内丸 薫; 東條 有伸, 臨床血液, 58(8), 1080-1081, Aug. 2017
  • 遺伝子組み換えワクシニアウイルスを用いた,多発性骨髄腫に対する腫瘍溶解ウイルス療法の開発, 佐藤広太; 二見宗孔; 中村貴史; 鈴木憲史; 今井陽一; 東條有伸, International Journal of Myeloma (Web), 7(1), ROMBUNNO.P1‐4 (WEB ONLY)-79, Apr. 2017
  • 遺伝子組み換えワクシニアウイルスを用いた、多発性骨髄腫に対する腫瘍溶解ウイルス療法の開発, 佐藤 広太; 二見 宗孔; 中村 貴史; 鈴木 憲史; 今井 陽一; 東條 有伸, International Journal of Myeloma, 7(1), 79-79, Apr. 2017
  • Serum Soluble SLAMF7 is Correlated With Disease Progression in Multiple Myeloma and May Affect Anti-SLAMF7 Antibody Therapy, Yuta Kaito; Hideto Tamura; Saori Soeda; Toshio Asayama; Mariko Ishibashi; Makoto Sasaki; Hiroshi Handa; Yoichi Imai; Junji Tanaka; Sakae Tanosaki; Shigeki Ito; Koiti Inokuchi, CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17(1), E39-E40, Feb. 2017
    DOI
  • Clinical Impact and Possible Immunosuppressive Function of Soluble B7-H1 (PD-L1) in Multiple Myeloma, Mika Sunakawa; Hideto Tamura; Mariko Ishibashi; Makoto Sasaki; Hiroshi Handa; Yoichi Imai; Junji Tanaka; Sakae Tanosaki; Shigeki Ito; Koiti Inokuchi, CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17(1), E110-E111, Feb. 2017
    DOI
  • 成人T細胞白血病リンパ腫同種移植後単一臓器再発症例の臨床像, 小川弥穂; 今井陽一; 平野光人; 神保光児; 越智清純; 川俣豊隆; 横山和明; 大野伸広; 福田隆浩; 内丸薫; 内丸薫; 東條有伸, 日本HTLV-1学会学術集会, 4th, 2017
  • ATL患者の同種造血幹細胞移植後に慢性炎症性脱髄性多発ニューロパチーを発症した3症例の解析, 平野光人; 今井陽一; 神保光児; 小川弥穂; 越智清純; 川俣豊隆; 横山和明; 横山和明; 大野伸広; 山野嘉久; 福田隆浩; 内丸薫; 内丸薫; 東條有伸; 東條有伸, 日本HTLV-1学会学術集会, 4th, 2017
  • 免疫関連分子SLAMF3による多発性骨髄腫の増悪化メカニズム, 石橋真理子; 田村秀人; 高橋理紗; 坪田朝子; 朝山敏夫; 栗林泰子; 小野寺麻加; 守屋慶一; 今井陽一; 半田寛; 佐々木純; 小松則夫; 田野崎栄; 伊藤薫樹; 猪口孝一, International Journal of Myeloma (Web), 7(1), ROMBUNNO.SY1‐2 (WEB ONLY)-35, 2017
  • Exploratory Introduction of Cognitive Computing to Clinical Sequencing in Hematological Malignancies, Kazuaki Yokoyama; Nozomi Yusa; Mika Itoh; Asako Suzuki; Sosuke Nakamura; Miho Ogawa; Koji Jimbo; Masayuki Kobayashi; Toyotaka Kawamata; Takaaki Konuma; Rika Kasajima; Hiroaki Yui; Eigo Shimizu; Takahiko Koyama; Nobuhiro Ohno; Yoichi Imai; Satoshi Takahashi; Kaoru Uchimaru; Rui Yamaguchi; Seiya Imoto; Yoichi Furukawa; Satoru Miyano; Arinobu Tojo, BLOOD, 128(22), Dec. 2016
    DOI
  • Clinical Profile and BRAF Status of 30 Japanese Patients with Adult Langerhans Cell Histiocytosis, Miho Ogawa; Masayuki Kobayashi; Koji Jimbo; Toyotaka Kawamata; Kazuaki Yokoyama; Nobuhiro Ohno; Yoichi Imai; Satoshi Takahashi; Arinobu Tojo, BLOOD, 128(22), Dec. 2016
  • Genomic analysis of AML and its clinical application, 今井 陽一, 血液内科 = Hematology, 72(5), 569-573, May 2016
  • 多発性骨髄腫における血清可溶性SLAMF7の臨床的意義, 添田沙織; 田村秀人; 石橋真理子; 磯田淳; 松本守生; 佐々木純; 小松則夫; 半田寛; 今井陽一; 田野崎栄; 伊藤薫樹; 石田陽治; 小池道明; 猪口孝一, International Journal of Myeloma (Web), 6(2), ROMBUNNO.P‐58 (WEB ONLY)-130, 2016
  • 可溶型B7‐H1(PD‐L1)の機能と多発性骨髄腫患者おける臨床的意義, 砂川実香; 田村秀人; 石橋真理子; 今井陽一; 半田寛; 佐々木純; 小松則夫; 田野崎栄; 磯田淳; 松本守生; 伊藤薫樹; 石田陽治; 小池道明; 猪口孝一, International Journal of Myeloma (Web), 6(2), ROMBUNNO.P‐9 (WEB ONLY)-82, 2016
  • 形質細胞性白血病となり増悪したKL‐6産生骨髄腫の1例と骨髄腫におけるKL‐6の臨床的解析, 山田晃子; 田村秀人; 石橋真理子; 佐々木純; 今井陽一; 半田寛; 田野崎栄; 伊藤薫樹; 石田陽治; 磯田淳; 松本守生; 小池道明; 小松則夫; 猪口孝一, International Journal of Myeloma (Web), 6(2), ROMBUNNO.P‐14 (WEB ONLY)-87, 2016
  • Fractionated ICE with Rituximab Is Safe and Effective for Relapse/Refractory DLBCL Patients with Severe Comorbidities, Norina Tanaka; Yoichi Imai; Aya Watanabe; Kenjiro Mitsuhashi; Kentaro Yoshinaga; Masayuki Shiseki; Naoki Mori; Junji Tanaka, BLOOD, 126(23), Dec. 2015
  • Retrospective Analysis of Treatment Outcomes for Patients with Follicular Lymphoma and Comorbidities, Aya Watanabe; Yoichi Imai; Kenjiro Mitsuhashi; Akihito Shinohara; Norina Tanaka; Kentaro Yoshinaga; Masayuki Shiseki; Naoki Mori; Junji Tanaka, BLOOD, 126(23), Dec. 2015
  • Side effects with long term use of tyrosine kinase inhibitors for chronic myeloid leukemia patients, SHINOHARA Akihito; SHISEKI Masayuki; TANAKA Norina; MITSUHASHI Kenjiro; HIRAI Yuji; ISHIYAMA Midori; KAZAMA Hiroshi; YOSHINAGA Kentaro; IMAI Yoichi; MORI Naoki; TANAKA Junji, 臨床血液, 56(9), 1401, 30 Sep. 2015
  • A retrospective analysis of divided R-ICE therapy for relapsed or refractory DLBCL, TANAKA Norina; IMAI Yoichi; WATANABE Aya; MITSUHASHI Kenjiro; SHINOHARA Akihito; YOSHINAGA Kentaro; SHISEKI Masayuki; MORI Naoki; TANAKA Junji, 臨床血液, 56(9), 1507, 30 Sep. 2015
  • 骨髄腫における増殖因子IL‐6およびIGF‐1とそれらレセプター発現の臨床的意義:KTMM多施設共同研究, 守屋慶一; 石橋真理子; 田村秀人; 半田寛; 佐々木純; 磯田淳; 今井陽一; 伊藤薫樹; 田野崎栄; 猪口孝一; 小松則夫; 松本守生; 田中淳司; 石田陽治; 小池道明, Int J Myeloma (Web), 5(2), O-33 (WEB ONLY)-74, 2015
  • 多発性骨髄腫におけるB型肝炎ウィルス再活性化に関する検討:KTMM多施設共同研究, 築根豊; 八幡悠里子; 佐々木純; 田村秀人; 小野寺麻加; 小池道明; 伊藤薫樹; 石田陽治; 今井陽一; 田中淳司; 磯田淳; 松本守生; 田野崎栄; 小松則夫, Int J Myeloma (Web), 5(2), O-1 (WEB ONLY), 2015
  • 骨髄腫細胞に発現するB7‐H1(PD‐L1)分子の逆シグナル伝達と臨床的インパクト, 石橋真理子; 田村秀人; 砂川実香; 磯田淳; 松本守生; 佐々木純; 小松則夫; 半田寛; 今井陽一; 田野崎栄; 伊藤薫樹; 石田陽治; 小池道明; 猪口孝一, Int J Myeloma (Web), 5(2), O-26 (WEB ONLY)-67, 2015
  • 骨髄腫におけるSLAMファミリー分子SLAMF3とSLAMF7の発現と機能, 山田晃子; 田村秀人; 石橋真理子; 磯田淳; 佐々木純; 半田寛; 今井陽一; 小池道明; 伊藤薫樹; 守屋慶一; 小野寺麻加; 奥山奈美子; 濱田泰子; 朝山敏夫; 小松則夫; 田中淳司; 石田陽治; 田野崎栄; 猪口孝一, Int J Myeloma (Web), 5(2), O-27 (WEB ONLY)-68, 2015
  • Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine, Noriko Isono; Yoichi Imai; Chihiro Asano; Michihiko Masuda; Shigeru Hoshino; Keiichi Moriya; Hideto Tamura; Koiti Inokuchi; Shigeki Ito; Yoji Ishida; Toshiko Motoji; Junji Tanaka, BLOOD, 124(21), Dec. 2014
  • Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma, Akiko Yamada; Hideto Tamura; Mariko Ishibashi; Koiti Inokuchi; Makoto Sasaki; Yuriko Yahata; Norio Komatsu; Atsushi Isoda; Morio Matsumoto; Hiroshi Handa; Yoichi Imai; Junji Tanaka; Sakae Tanosaki; Shigeki Ito; Yoji Ishida; Michiaki Koike, BLOOD, 124(21), Dec. 2014
  • Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy, Mariko Ishibashi; Hideto Tamura; Mika Sunakawa; Asaka Kondo-Onodera; Keiichi Moriya; Namiko Okuyama; Yasuko Hamada; Atsushi Isoda; Morio Matsumoto; Makoto Sasaki; Norio Komatsu; Hiroshi Handa; Yoichi Imai; Junji Tanaka; Sakae Tanosaki; Shigeki Ito; Yoji Ishida; Michiaki Koike; Koji Tamada; Koiti Inokuchi, BLOOD, 124(21), Dec. 2014
  • Knockdown of a Wnt Receptor FZD1 reduces MDR1/P-Glycoprotein Expression in Human Leukemia Cells through the Wnt/beta-Catenin Signaling Pathway, Yan-Hua Wang; Toshiko Motoji; Yoichi Imai; Masayuki Shiseki; Kenjiro Mitsuhashi; Ye Ding; Junji Tanaka, BLOOD, 124(21), Dec. 2014
  • RELAL-88 exhibited high remission rates in refractory or relapsed adult precursor lymphoid neoplasms, MITSUHASHI Kenjiro; KATSUMI Shigeaki; ISHIWA Michiko; ENOMOTO Yuki; ISHIMORI Noriko; YE Ding; SHIMURA Hanae; KODAMA Shoko; TANAKA Norina; ISHIYAMA Midori; KAZAMA Hiroshi; YOSHINAGA Kentaro; IMAI Yoichi; SHISEKI Masayuki; MORI Naoki; TANAKA Junji, 臨床血液, 55(9), 1279, 30 Sep. 2014
  • Discovered roles of MLL in pathogenesis of multiple myeloma, 今井 陽一; 太田 瑛里, 日本臨床, 72(6), 1047-1051, Jun. 2014
  • フロサイトメトリーによる骨髄腫細胞表面抗原の解析:関東‐東北骨髄腫カンファレンス多施設共同研究, 田村秀人; 石橋真理子; 猪口孝一; 磯田淳; 松本守生; 佐々木純; 小松則夫; 半田寛; 今井陽一; 田中淳司; 田野崎栄; 伊藤薫樹; 石田陽治; 小池道明, Int J Myeloma (Web), 4(2), O-22 (WEB ONLY)-87, 2014
  • MGUS及び多発性骨髄腫におけるFGFR3解析に関する検討:関東‐東北骨髄腫カンファレンス多施設共同研究, 八幡悠里子; 築根豊; 半田寛; 入内島裕乃; 磯田淳; 松本守生; 田村秀人; 石橋真理子; 猪口孝一; 今井陽一; 田中淳司; 田野崎栄; 小池道明; 伊藤薫樹; 石田陽治; 小松則夫; 佐々木純, Int J Myeloma (Web), 4(2), O-11 (WEB ONLY)-76, 2014
  • 私のこの一枚(115)腹腔内巨大腫瘍で発症した腎移植後リンパ増殖性疾患, 志村華絵; 今井陽一; 田中淳司, 血液フロンティア, 24(1), 5-10, 30 Dec. 2013
    DOI
  • Diagnosis and therapy of plasma cell leukemia : recommendations by the International Myeloma Working Group, 今井 陽一, 血液内科, 67(5), 676-682, Nov. 2013
  • Thrombotic thrombocytopenic purpura diagnosed after a twenty-year history of thrombocytopenia, SHIMURA Hanae; KODAMA Shoko; YOSHINAGA Kentaro; MATSUMOTO Masanori; FUJIMURA Yoshihiro; ENOMOTO Yuki; IMAI Yoichi; SHISEKI Masayuki; MORI Naoki; TERAMURA Masanao; MOTOJI Toshiko, 臨床血液, 54(9), 1465, 30 Sep. 2013
  • Donor cell leukemia after cord blood transplantation: Compareing to BM as transplanted source, SHIOZAKI Hiroko; YOSHINAGA Kentaro; KONDO Toshiaki; IMAI Yoichi; SHISEKI Masayuki; MORI Naoki; TERAMURA Masanao; MOTOJI Toshiko, 臨床血液, 54(9), 1339, 30 Sep. 2013
  • G6PD異常症を合併した鎌状赤血球症の1例, 志村華絵; 今井陽一; 吉永健太郎; 志関雅幸; 森直樹; 田中淳司; 菅野仁, 臨床血液, 54(11), 2013
  • Successfully treated eldery blastic plasmacytoid dendritic cell neoplasm with t(6;8)(p21;q24), SHIMURA Hanae; IMAI Yoichi; KONDO Toshiaki; OKAMURA Takamitsu; KANEKO Nao; TSUNEMI Yuichiro; SHISEKI Masayuki; MORI Naoki; TERAMURA Masanao; MOTOJI Toshiko, 臨床血液, 53(9), 1192, 30 Sep. 2012
  • ランダム皮膚生検にて診断しえた血管内大細胞型B細胞リンパ腫, 清水 悠里; 近藤 年昭; 志村 華絵; 田中 紀奈; 三橋 健次郎; 風間 啓至; 安並 毅; 岡村 隆光; 吉永 健太郎; 今井 陽一; 志関 雅幸; 森 直樹; 寺村 正尚; 泉二 登志子, 臨床血液, 53(5), 553-553, May 2012
  • ロミプロスチムと大量ガンマグロブリン療法により脾摘が可能となった難治性特発性血小板減少性紫斑病, 三橋 健次郎; 石山 みどり; 今井 陽一; 志関 雅幸; 森 直樹; 寺村 正尚; 瀬下 明良; 泉二 登志子, 東京女子医科大学雑誌, 82(2), 106-106, 25 Apr. 2012
  • 急速に進行し腫瘍崩壊症候群による慢性腎臓病の急性増悪をきたした移植後リンパ増殖性疾患, 近藤 朗子; 近藤 年昭; 石田 英樹; 今井 陽一; 志関 雅幸; 森 直樹; 寺村 正尚; 田邉 一成; 泉二 登志子, 東京女子医科大学雑誌, 82(1), 42-42, Feb. 2012
  • Blastic plasmacytoid dendritic cell neoplasmの1例, 大藤 由佳; 蘆田 龍一; 大松 華子; 菅谷 誠; 菊池 かな子; 玉置 邦彦; 齋藤 俊樹; 山本 豪; 今井 陽一; 高橋 強志; 黒川 峰夫, 日本皮膚科学会雑誌, 122(1), 139-140, Jan. 2012
    DOI
  • Prolonged activated partial thromboplastin time in a case of CMV-related infectious mononucleosis, SHIMURA Hanae; IMAI Yoichi; SHISEKI Masayuki; MORI Naoki; TERAMURA Masanao; MOTOJI Toshiko, 臨床血液, 52(9), 1176, 30 Sep. 2011
  • Long-term clinical outcome of patients with chronic myeloid leukemia treated with interferon-alpha, SHISEKI Masayuki; YASUNAMI Takeshi; OKAMURA Takamitu; KONDO Toshiaki; KAZAMA Hiroshi; MITUHASHI Kenjiro; IMAI Yoichi; YAMADA Osamu; YOSHINAGA Kentaro; MORI Naoki; TERAMURA Masanao; MOTOJI Toshiko, 臨床血液, 52(9), 1196, 30 Sep. 2011
  • 後天性血友病A, 近藤 年昭; 三橋 健次郎; 石山 みどり; 風間 啓至; 安並 毅; 岡村 隆光; 吉永 健太郎; 今井 陽一; 志関 雅幸; 森 直樹; 寺村 正尚; 山田 修; 泉二 登志子, 東京女子医科大学雑誌, 81(3), 221-222, 25 Jun. 2011
  • 急性骨髄性白血病の寛解導入療法後の遷延する血小板減少は予後不良を予測する, 小林央; 市川幹; 南谷泰仁; 半下石明; 今井陽一; 黒川峰夫, 日本内科学会雑誌, 100, 149, 20 Feb. 2011
  • A ROLE OF HIGH DOSE THERAPY AS CONSOLIDATION AFTER RITUXIMAB-CONTAINING INDUCTION FOR HIGH RISK B CELL LYMPHOMA, Yasuhito Nannya; Kazuki Taoka; Go Yamamoto; Yoichi Imai; Mineo Kurokawa, ANNALS OF ONCOLOGY, 21, 41-41, Nov. 2010
  • Evil Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System, Keisuke Kataoka; Tomohiko Sato; Akihide Yoshimi; Susumu Goyama; Takako Tsuruta; Shunya Arai; Yoichi Imai; Katsuyoshi Kumagai; Naoto Kubota; Takashi Kadowaki; Mineo Kurokawa, BLOOD, 116(21), 365-365, Nov. 2010
  • A Critical Role of Reactive Oxygen Species In the Generation of Megakaryocyte-Erythrocyte Progenitor Cells, Akihito Shinohara; Yoichi Imai; Masahiro Nakagawa; Tsuyoshi Takahashi; Motoshi Ichikawa; Mineo Kurokawa, BLOOD, 116(21), 676-676, Nov. 2010
  • AML1/RUNX1 FUNCTIONS AS A CYTOPLASMIC ATTENUATOR OF NF-KB SIGNALING IN THE REPRESSION OF MYELOID TUMORS, M. Nakagawa; M. Shimabe; S. Arai; N. Watanabeo-Okochi; A. Yoshimi; N. Nishimoto; M. Ichikawa; Y. Nannya; Y. Imai; M. Kurokawa, EXPERIMENTAL HEMATOLOGY, 38(9), S81-S81, Sep. 2010
  • 亜ヒ酸治療後に一過性のPML‐RARα転写産物の増加を認めた分子生物学的再発の急性前骨髄球性白血病の1例, 小林央; 島祐介; 齋藤俊樹; 市川幹; 半下石明; 今井陽一; 黒川峰夫, 臨床血液, 51(3), 222-222, 30 Mar. 2010
  • Impacts of diagnostic and therapeutic advances on a clinical outcome of invasive aspergillosis in haematopoietic stem cell transplantation recipients, Y. Asano-Mori; Y. Kanda; K. Kandabashi; Y. Nanya; G. Yamamoto; S. Seo; M. Ichikawa; T. Saito; K. Kumano; A. Hangaishi; Y. Imai; T. Takahashi; M. Kurokawa, BONE MARROW TRANSPLANTATION, 45, S216-S216, Mar. 2010
  • 家族性血小板異常症から発症したt(1;7)転座を伴うTリンパ芽球性リンパ腫, 植田航希; 今井陽一; 南谷泰仁; 篠原明仁; 市川幹; 熊野恵城; 高橋強志; 半下石明; 黒川峰夫, 日本内科学会雑誌, 99, 238, 20 Feb. 2010
  • 同種造血幹細胞移植後の侵襲性アスペルギルス症に対する診断と治療の進歩, 森有紀; 神田善伸; 神田橋宏治; 南谷泰仁; 山本豪; 瀬尾幸子; 市川幹; 斉藤俊樹; 熊野恵城; 半下石明; 今井陽一; 高橋強志; 黒川峰夫, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 222, 2010
  • 急性膵炎を契機に診断されたバーキットリンパ腫の1例, 籠谷勇紀; 増田亜希子; 山本豪; 市川幹; 太田聡; 今井陽一; 深山正久; 黒川峰夫, 日本内科学会関東支部関東地方会, 571st, 20, 2010
  • Impact On Survival and Treatment of Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation., Koki Ueda; Takeyuki Watadani; Eriko Maeda; Satoshi Ota; Keisuke Kataoka; Sachiko Seo; Keiki Kumano; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Kuni Ohtomo; Masashi Fukayama; Yasuhito Nannya; Mineo Kurokawa, BLOOD, 114(22), 1286-1287, Nov. 2009
  • AML1/Runx1 Is a Cytoplasmic Attenuator of NF-Kb Signaling: Implication in Pathogenesis and Targeted Therapy of AML1-Related Leukemia., Masahiro Nakagawa; Munetake Shimabe; Nahoko Nishimoto; Naoko Watanabe-Okochi; Motoshi Ichikawa; Yasuhito Nannya; Yoichi Imai; Mineo Kurokawa, BLOOD, 114(22), 777-777, Nov. 2009
  • Erdheim-Chester disease(ECD)の1例, 成瀬 紘也; 成川 研介; 齋藤 俊樹; 岡本 明子; 山本 豪; 今井 陽一; 高橋 強志; 山本 一彦; 黒川 峰夫, 日本内科学会関東地方会, 565回, 28-28, Sep. 2009
  • 再発急性前骨髄球性白血病に対する亜ヒ酸による治療中に心嚢水・胸水貯留を生じた1例, 井山千草; 植田航希; 南谷泰仁; 市川幹; 熊野恵城; 半下石明; 高橋強志; 今井陽一; 黒川峰夫, 臨床血液, 50(8), 671, 30 Aug. 2009
  • Role of integrin in hematopoiesis and leukemia, 今井 陽一, 血液・腫瘍科, 59(2), 228-232, Aug. 2009
  • 悪性リンパ腫に対するR‐CHOP療法後にreversible posterior leukoencephalopathy syndromeを発症した1例, 藤岡洋成; 細井雅孝; 山本豪; 浅野大樹; 南谷泰仁; 神田橋宏治; 瀬尾幸子; 市川幹; 熊野恵城; 半下石明; 高橋強志; 今井陽一; 黒川峰夫, 臨床血液, 50(4), 318-319, 30 Apr. 2009
  • Evi-1 Interacts with Histone Methyltransferases for Transcription Repression and Bone Marrow Transformation, Susumu Goyama; Eriko Nitta; Munetake Shimabe; Tetsuya Yoshino; Shinichi Kako; Motoshi Ichikawa; Yoichi Imai; Tsuyoshi Takahashi; Akira Hangaishi; Mineo Kurokawa, BLOOD, 112(11), 787-788, Nov. 2008
  • Relationships Between Late Viral Infections and Immune Reconstitution after Hematopoietic Stem Cell Transplantation, Yum Asano-Mori; Yoshinobu Kanda; Kumi Oshima; Yasuhito Nanya; Keiki Kumano; Takashi Asai; Akira Hangaishi; Tsuyoshi Takahashi; Yoichi Imai; Mineo Kurokawa, BLOOD, 112(11), 419-419, Nov. 2008
  • Pbx-1 Is a Direct Target of Evi-1 in Hematopoietic Stem/Progenitors and Leukemic Cells, Munetake Shimabe; Susuma Goyama; Motoshi Ichikawa; Yoichi Imai; Tsuyoshi Takahashi; Akira Hangaishi; Mineo Kurokawa, BLOOD, 112(11), 435-435, Nov. 2008
  • 移植後血算データが同種造血幹細胞移植成績に与える影響, 南谷泰仁; 片岡圭亮; 熊野恵城; 浅井隆司; 渡辺卓郎; 山本豪; 市川幹; 半下石明; 今井陽一; 高橋強志; 千葉滋; 黒川峰夫, 臨床血液, 49(9), 876, 30 Sep. 2008
  • 肺真菌症の所見を有する同種造血幹細胞移植患者に対する新規抗真菌剤による再活性化の予防効果, 岡田純卓; 南谷泰仁; 熊野恵城; 浅井隆司; 渡辺卓郎; 山本豪; 市川幹; 半下石明; 今井陽一; 高橋強志; 千葉滋; 黒川峰夫, 臨床血液, 49(9), 1218, 30 Sep. 2008
  • 鉄過剰状態が同種造血幹細胞移植成績に与える影響, 片岡圭亮; 南谷泰仁; 熊野恵城; 浅井隆司; 渡辺卓郎; 山本豪; 市川幹; 半下石明; 今井陽一; 高橋強志; 千葉滋; 黒川峰夫, 臨床血液, 49(9), 1161, 30 Sep. 2008
  • 白血病標的遺伝子Evi‐1によるヒストンメチル化修飾を介した転写制御機構, 合山進; 仁田英里子; 島辺宗健; 吉野哲也; 市川幹; 今井陽一; 高橋強志; 黒川峰夫, 臨床血液, 49(9), 880, 30 Sep. 2008
  • 造血幹細胞におけるAML1/Runx1の転写標的ネットワークの解明, 中川正宏; 今井陽一; 市川幹; 浅井隆司; 黒川峰夫, 臨床血液, 49(9), 878, 30 Sep. 2008
  • 白血病標的遺伝子Evi‐1によるPBX‐1の発現制御機構, 島辺宗健; 合山進; 市川幹; 今井陽一; 高橋強志; 半下石明; 黒川峰夫, 臨床血液, 49(9), 916, 30 Sep. 2008
  • MLL融合遺伝子によるEvi‐1の発現制御機構, 荒井俊也; 合山進; 島辺宗健; 市川幹; 今井陽一; 高橋強志; 半下石明; 黒川峰夫, 臨床血液, 49(9), 881, 30 Sep. 2008
  • AML1による造血幹細胞制御と白血病発症機構, 西本菜穂子; 市川幹; 中川正宏; 合山進; 高橋強志; 今井陽一; 黒川峰夫, 臨床血液, 49(9), 916, 30 Sep. 2008
  • 骨髄異形成症候群に対する同種骨髄移植後に急性好酸球性肺炎を生じた1例, 寺田美奈; 吉見真弓; 南谷泰仁; 山本豪; 市川幹; 渡辺卓郎; 浅井隆司; 半下石明; 高橋強志; 今井陽一; 黒川峰夫; 熊野恵城; 千葉滋, 臨床血液, 49(7), 529, 30 Jul. 2008
  • 子宮浸潤を伴った慢性骨髄単球性白血病の1例, 那須涼; 片岡圭亮; 市川幹; 吉見昭秀; 浅井隆司; 半下石明; 高橋強志; 今井陽一; 黒川峰夫, 日本内科学会関東支部関東地方会, 555th, 18, 2008
  • A solid tumor of donor cell-origin after allogeneic peripheral blood stem cell transplantation, Y. Arai; H. Arai; A. Aoyagi; T. Yamagata; K. Mitani; K. Kubota; H. Kawamata; Y. Imai, AMERICAN JOURNAL OF TRANSPLANTATION, 6(12), 3042-3043, Dec. 2006
    DOI
  • Ki23819 (KRN383 center dot HCI) inhibits kinase activity of wild type and mutant FLT3 receptor tyrosine kinase in vitro., Y Komeno; M Kurokawa; Y Imai; M Takeshita; T Matsumura; K Kubo; T Yoshino; U Nishiyama; T Kuwaki; K Kubo; T Osawa; S Ogawa; S Chiba; A Miwa; H Hirai, BLOOD, 104(11), 331A-331A, Nov. 2004
  • Oligomerization of Evi-1 contributes to recruitment of transcriptional corepressor CtBP and repression of TGF-beta signaling, E Nitta; K Izutsu; Y Yamaguchi; Y Imai; S Ogawa; S Chiba; M Kurokawa; H Hirai, BLOOD, 104(11), 703A-704A, Nov. 2004
  • High-grade CMV antigenemia after hematopoietic stem cell transplantation: Risk factor and outcome., Y Asano; Y Kanda; MS Yanagimoto; M Nakagawa; K Kandabashi; K Izutsu; Y Imai; A Hangaishi; M Kurokawa; S Tsujino; S Ogawa; S Chiba; T Motokura; H Hirai, BLOOD, 102(11), 441B-441B, Nov. 2003
  • Identification of a novel fusion gene, TTL, fused to TEL, in acute lymphoblastic leukemia with t(12;13)(p13;q14) and its implication in leukemogenesis., Q Ying; S Ogawa; A Hangaishi; K Yuji; K Izutsu; A Kunisato; Y Imai; LL Wang; N Hosoya; Y Sato; Y Nakamura; K Mitani; H Hirai, BLOOD, 100(11), 532A-532A, Nov. 2002
  • Notch1 activation represses TGF-beta(/)Smad signaling via the transcriptional coactivator p300., S Masuda; S Chiba; K Kumano; A Kunisato; T Saito; E Yamaguchi; T Yamaguchi; K Izutsu; Y Imai; M Kurokawa; H Hirai, BLOOD, 100(11), 737A-737A, Nov. 2002
  • The interaction between AML1/RUNX1 and the corepressor mSin3A regulates phosphorylation-induced transcriptional activation, intranuclear location, and stability of AML1/RUNX1., Y Imai; M Kurokawa; Y Yamaguchi; K Mitani; H Hirai, BLOOD, 100(11), 65A-65A, Nov. 2002
  • AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues., H Hirai; Y Yamaguchi; M Kurokawa; Y Imai; K Izutsu; T Asai; M Ichikawa; G Yamamoto; E Nitta; T Yamagata; K Mitani, BLOOD, 100(11), 31A-31A, Nov. 2002
  • p300を介するAML1のアセチル化による機能制御, 山口祐子; 黒川峰夫; 今井陽一; 伊豆津宏二; 浅井隆; 市川幹; 山本豪; 三谷絹子; 平井久丸, 日本癌学会総会記事, 61st, 86, 25 Aug. 2002
  • The t(3;21) fusion product, AML1/Evi-1, blocks AML1-induced transactivation by recruiting CtBP., K Izutsu; M Kurokawa; Y Imai; K Mitani; H Hirai, BLOOD, 98(11), 833A-834A, Nov. 2001
  • Mutations of a checkpoint gene, Chk2, in primary hematopoietic malignancies., A Hangaishi; S Ogawa; Q Ying; W Lili; N Hosoya; Y Imai; K Yuji; H Hirai, BLOOD, 96(11), 173B-173B, Nov. 2000
  • The corepressor CtBP is involved in Evi-1 mediated repression of TGF-beta signaling., K Izutsu; M Kurokawa; Y Imai; K Mitani; H Hirai, BLOOD, 96(11), 90A-90A, Nov. 2000
  • The t(3;21) fusion product, AML1/Evi-1, interacts with Smad3 and blocks transforming growth factor-beta-mediated growth inhibition of myeloid cells., M Kurokawa; K Mitani; Y Imai; S Ogawa; Y Yazaki; H Hirai, EXPERIMENTAL HEMATOLOGY, 27(7), 61-61, Jul. 1999
  • The AML1/ETO(MTG8) and AML1/EVI-1 leukemia-associated chimeric oncoproteins accumulate PEBP2 beta(CBF beta) in the nucleus more efficiently than wild-type AML1., K Tanaka; T Tanaka; M Kurokawa; Y Imai; S Ogawa; SW Hiebert; K Mitani; Y Yazaki; H Hirai, BLOOD, 88(10), 2188-2188, Nov. 1996
  • 特集：多発性骨髄腫update IV.診断と治療 治療の進歩 多発性骨髄腫に対する抗体医薬の意義と展望, 今井陽一, 日本臨床, 81(6), 915-921, 2023
  • 連載 血液専門医講座 血液専門医のための模擬テスト34―解答と解説―, 今井陽一, 血液内科, 86(1), 147-149, 2023
  • 連載 血液専門医講座 血液専門医のための模擬テスト34, 今井陽一, 血液内科, 85(6), 894-894, 2023
  • Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma, Mitsuhito Hirano; Yoichi Imai; Takahiko Murayama; Kota Sato; Junichi Yamamoto; Takumi Ito; Muneyoshi Futami; Masaki Ri; Hiroshi Yasui; Noriko Gotoh; Shinsuke Iida; Tadao Ishida; Hiroshi Handa; Arinobu Tojo, BLOOD, 134, Nov. 2019
    DOI
  • t(4;14)陽性骨髄腫患者におけるFGFR3過剰発現は予後不良に関与しない, 木下量介; 石橋真理子; 半田寛; 佐々木純; 小松則夫; 今井陽一; 伊藤薫樹; 田中紀奈; 田中淳司; 磯田淳; 松本守生; 田野崎栄; 砂川実香; 朝山敏夫; 猪口孝一; 田村秀人; 田村秀人, 日本血液学会学術集会抄録(Web), 82nd, 2020

Books etc

  • 多発性骨髄腫の診療指針 第5版 日本骨髄腫学会編, Contributor, 文光堂, Oct. 2020
  • 内科学書 中山書店 改訂第9版 Vol. 6, Contributor, 今井 陽一, 血液・造血器疾患 6 白血球系を主病変とする疾患 免疫グロブリン異常（多発性骨髄腫、マクログロブリン血症、意義不明の単クローン性免疫グロブリン血症、H鎖病、ALアミロイドーシス、その他の免疫グロブリン異常、196-208, 中山書店, Aug. 2019, Not refereed
  • Heat Shock Proteins in Signaling Pathways, Contributor, Yoichi Imai; Arinobu Tojo, Regulation of Calcineurin Signaling Through Blocking of the Chaperone Function of Hsp90 by HDAC Inhibitors., Springer, Jul. 2019, Not refereed
  • What's New in Oncology がん治療エッセンシャルガイド 改訂4版, Contributor, 今井 陽一, 23. 多発性骨髄腫, 南山堂, May 2019, Not refereed
  • EBM血液疾患の治療 2019-2020 edition, Contributor, 今井 陽一, V. 多発性骨髄腫と関連疾患 7形質細胞性白血病の治療, 中外医学社, 2018, Not refereed
  • 血液疾患 最新の治療2017-2019, Contributor, 今井 陽一, 6全身疾患に伴う貧血, 南江堂, 2017, Not refereed
  • 今日の治療指針2016年版, Contributor, 今井 陽一, 赤芽球癆 pure red cell aplasia (PRCA), 医学書院, 2016, Not refereed
  • ブラッシュアップ多発性骨髄腫, Contributor, 今井 陽一, 多発性骨髄腫に対するRisk-adapted strategyの現状と展望, 中外医学社, 2015, Not refereed
  • Principles and practice 血液・造血器・リンパ系, Contributor, 今井 陽一, 5章 疾患の病因、病態、診断と治療 32 巨赤芽球性貧, 文光堂, 2015, Not refereed
  • プリンシプル血液疾患の臨床, Contributor, 今井 陽一, 第４章 骨髄腫総論 骨髄腫の分子病態、リンパ腫・骨髄腫の最新療法, 中山書店, 2014, Not refereed
  • 多発性骨髄腫Updating 第3巻 多発性骨髄腫の治療目標～初期治療のエンドポイントから再発例の治療目標まで～, Contributor, 今井 陽一, V.再発の定義と再発例の治療目標, 医薬ジャーナル社, 2013, Not refereed
  • 症例から学ぶメディカルオンコロジー, Contributor, 今井陽一; 三橋健次郎; 泉二登志子, V血液癌, 8. DICで発症したAPL, 医薬ジャーナル社, 2011, Not refereed

Presentations

  • Mechanism of action and clinical results of immunotherapy for multiple myeloma, 今井陽一, 第84回日本血液学会学術集会, 15 Oct. 2022, Invited oral presentation
  • 進化する多発性骨髄腫の診断と治療, 今井陽一, 第4回日本血液学会関東甲信越地方会若手教育セミナー, 11 Jun. 2022
  • 血液内科学における未来PET―医工連携による新規診断技術創出, 今井陽一, 「未来PET創造研究ユニット」キックオフ Bench to Clinicalシンポジウム, 29 May 2022
  • Action mechanisms of BCMA -targeted therapies for multiple myeloma and their promising and exciting clinical results in relapse/refractory patients. Recent advances in targeted therapy for B-cell malignancies., 今井 陽一, 第19回日本臨床腫瘍学会学術集会, 17 Feb. 2022, Nominated symposium
  • Expectations for next generation PET as a hematologist, 今井陽一, QST（量子科学技術研究開発機構） International Research Initiative Symposium 次世代PET研究会2021, 23 Jan. 2021
  • 「抗体医薬の進歩～ADC(抗体薬物複合体)、二重特異性(BiTE)抗体まで～」, 今井 陽一, 第58回日本癌治療学会学術集会臓器別シンポジウム3 造血器腫瘍に対する免疫治療戦略, 22 Oct. 2020
  • 新規診断多発性骨髄腫の病態とIMiDsの作用機序, 今井 陽一, 第82回日本血液学会学術集会ランチョンセミナー2-2, 10 Oct. 2020
  • HDAC and AKT inhibitors enhance anti-myeloma effects of daratumumab., Mitsuhito Hirano; Yoichi Imai; Wengchif Ung; Kota Sato; Muneyoshi Futami; Arinobu Tojo, 第80回日本血液学会学術集会, 2018, Oral presentation, False
  • HDAC and AKT inhibitors enhance anti-myeloma effects of dartumumab., 平野 光 人; 今井 陽一; 二見 宗孔; 東條 有伸, 第77回日本癌学会学術総会, 2018, Oral presentation, False
  • Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis., Hirano M; Imai Y; Ung WC; Sato K; Futami M; Tojo A, 60th American Society of Hematology Annual Meeting, 2018, Poster presentation, True
  • 骨髄腫治療におけるHDAC阻害による細胞内シグナル阻害と腫瘍免疫賦活化 （シンポジウム）, 今井 陽一; 平野光人; 佐藤広太; 二見宗孔; 東條有伸, 第43回日本骨髄腫学会学術集会, 2018, Invited oral presentation, False
  • AMLの遺伝子異常に基づいた治療戦略 （教育講演）, 今井 陽一, 第77回日本血液学会学術集会, 2015, Invited oral presentation, False
  • 「血液がんー不治の病から治る時代へ」, 今井陽一, 令和５年度獨協医科大学公開講座, 03 Jun. 2023, Public discourse
  • 多発性骨髄腫の免疫療法―既存抗体の作用メカニズム・治療成績からCAR-T細胞療法、bispecific antibodyの現状・開発状況まで From basic and clinical studies of monoclonal antibodies for MM to the current and future status of therapy of CAR-T cell and bispecific antibodies, 今井陽一, 第48回日本骨髄腫学会学術集会、シンポジウム1骨髄腫治療の限界の打破を目指して 免疫療法の新展開 New developments of immunotherapy, 27 May 2023, Nominated symposium
  • Strategy for maintenance therapy for transplant-eligible and non-eligible patients with multiple myeloma in JAPAN., Yoichi Imai, Symposium title: Optimizing MM Maintenance Management with Oral Proteasome Inhibitor。TSH (Thailand Society of Hematology) -IS Bangkok 2023 (8th International Symposium and 61st Annual Meeting of TSH), 09 May 2023, Invited oral presentation
  • Ixazomib maintenance therapy for MM in Japan., Yoichi Imai, Takeda APAC Oncosummit, 17 Feb. 2023, Invited oral presentation

Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.